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Abstract 
Zhen Guo 
Insights of Taste Masking from Molecular Interactions and Microstructures of 
Microspheres  
Keywords: Taste Masking, Cyclodextrin, Lipid Microspheres, Kinetics, 
Synchrotron Radiation, Surface Plasmon Resonance Imaging, High 
Performance Affinity Chromatography 
The effects of taste masking are determined by interactions between drug and 
excipients as well as the microstructures of the particulate drug delivery 
systems (DDS). Cyclodextrin (CD) is a widely used taste masking agent, to 
which the relationship between kinetic parameters (Ka and Kd) of a drug and 
taste masking remains unexplored, which is investigated for the first time in this 
study. A data base of the kinetic parameters for drug-CD was established by 
Surface Plasmon Resonance Imaging (SPRi) and High Performance Affinity 
Chromatography (HPAC). Combined with the electronic tongue, Ka and Kd 
based models for the taste masking effect of HP-β-CD were successfully 
established and applied to the prediction of taste masking effects. Paracetamol 
was used as a model drug for taste masking formulation optimization. As well 
as drug release the microstructure of solid DDS has considerable influence on 
drug taste. The microstructure of lipid microspheres and the molecular 
distribution of drug and excipients in lipid microspheres were investigated by 
Synchrotron radiation-based micro-computed tomography (SR-µCT) and 
Synchrotron radiation-based Fourier-transform infrared spectromicroscopy (SR-
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FTIR), respectively. The results demonstrated that the polymeric formulation 
components as well as shape and particle size of the drug were the key factors 
to taste masking of paracetamol by inhibiting bust release thereby reducing the 
interaction intensity of the bitterness. The FTIR absorption spectra confirmed 
the deposition and formation of chitosan and gelatin films on the drug 
microsphere surface by layer-by-layer coating. In conclusion, this research 
demonstrates the molecular kinetic basis of CD taste-masking as well as 
microstructural basis of particle systems for bitter taste masking.  
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Chapter 1 Introduction  
 
The taste of an active pharmaceutical ingredient (API) plays a critical role in 
orally administered medicines. APIs may taste bitter and/or irritate the mouth 
and throat and thus are unpleasant not only to children but also to many adults. 
Undesirable taste is one of the top factors influencing the patient compliance. 
Therefore, research on the bitter taste mechanism, flavouring and taste 
masking technologies are of significant interest especially in paediatric 
medicines. 
Bitter tasting compounds can be amino acids and peptides, esters and lactones, 
phenols and polyphenols, flavonoids and terpenes, methylxanthines, sulfimides 
(notably saccharin), and organic and inorganic salts [1]. The fact that such 
structurally diverse compounds can elicit a single bitter taste suggests that 
multiple mechanisms are responsible for the perception and transduction of 
bitterness [2, 3]. Some of these mechanisms may be common to the perception 
of both bitter and sweet taste. Small changes in chemical structure can convert 
bitter compounds to intensely sweet or vice versa. For example, L-tryptophan is 
bitter but D-tryptophan is sweet. Bitter and sweet taste in solution can enhance 
or suppress each other, with the interplay between bitter and sweet occurring at 
the neuronal level [4]. The ability to perceive some bitter tastes varies greatly 
across individuals. 
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On a cellular level, the various tastants are recognized by taste receptor cells, 
which are within the oral cavity assembled to taste buds consisting of about 100 
cells. Four cell types can be distinguished based on their morphological and 
physiological characteristic: type-I cells serve a glial-like function, type-II cells 
express, strictly separated in distinct subsets, taste receptor proteins specific for 
sweet, umami, and bitter tastants, type-III cells are the only cell type within the 
taste bud capable of forming synapses with afferent nerve fibers and express 
sour taste receptors and, finally, type-IV cells are precursor cells able to 
differentiate throughout an individual‟s lifetime [5]. 
 
Figure 1 Taste buds located in the tongue 
(https://sites.google.com/a/bcssd.com/painter/anatomy-physiology/07-special-
senses) 
  3 
Taste transduction begins, when a stimulus comes into contact with a taste 
receptor cell. Whereas each taste bud may contain 75-150 epithelial cells, only 
a few are exposed at the taste pore at any one time [2]. Most taste buds are 
clustered in fungiform, foliate, and circumvallate papillae on the tongue surface, 
though some can also be found on the soft palate, epiglottis, and pharynx.  As a 
result, taste sensation can differ with the proportion of taste buds that are 
stimulated, depending on whether the stimulus is swallowed or not [6]. 
Taste stimuli can influence the receptor cells in a variety of ways. One of the 
most important pathways involves a G-Protein Coupled Receptor (GPCR) that 
stimulates enzyme-activated inositol-1,4,5-trisphosphate (IP3), leading to a 
release of calcium from cell stores (Figure 2).  
 
Figure 2 The bitter taste signal transduction cascade. Bitter taste receptors are 
G-protein-coupled receptors. Activation of TAS2Rs results in the activation of 
the heterotrimeric G-protein complex α-gustducin (α-gust), 3 or β1, and γ13. 
The βγ-subunits activate phospholipase C β2, (PLCβ2) resulting in the 
production of inositol 1,4,5-trisphosphate (IP3). The IP3-mediated increase of 
intracellular calcium activates transient receptor potential channel 5 (TRPM5) [7] 
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The number of different bitter taste receptors in humans (hTas2Rs) is estimated 
to be at least 25 [8]. The bitter taste receptor genes are organized in the 
genome in clusters and are genetically linked to loci that influence bitter 
perception in humans (and mice) [9]. The hTas2Rs are expressed in all taste 
buds of circumvallate and foliate papillae, and in palate taste buds. Whereas, 
hTas2Rs are rarely expressed in fungiform papillae, those fungiform taste buds 
that do express T2Rs have a full repertoire of different receptors, suggesting 
that each cell may recognize multiple bitter tastants. The limited number of bitter 
taste receptors detects an enormous number of structurally different bitter 
compounds [10]. It is therefore necessary that a given taste receptor responds 
to more than one substance, implying that the TAS2Rs are broadly tuned which 
increases the number of agonists stimulating a bitter taste receptor. Besides, 
hTas2Rs receptors are highly specialized. The human bitter taste receptor 
(hTas2R-4), which was the first human receptor to be deorphanized responded 
only to denatonium and 6-n-propylthiouracil, whereas a mouse receptor 
(MTas2R-5) responded only to cycloheximide [11]. Moreover, the bitter taste 
receptor genes of mammals not only lead to variability of bitter taste perception 
across species, but also show a considerable degree of intraspecies variability 
observed in mouse strains [12] and humans [13-19]. 
 
Different taste masking technologies have been used to address the problem of 
patient compliance, including coating, granulation, sweeteners, 
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microencapsulation, taste suppressants and potentiators, solid dispersions, ion 
exchange resins, viscosity enhancers, inclusion formation, pH modifiers and  
adsorbates [20]. 
(a) Coating 
Coating is one of the most efficient and commonly used taste masking 
technologies. Here, it is classified based on the type of coating material, coating 
solvent system, and the number of coating layers. Hydrophobic polymers, lipids, 
sweeteners and hydrophilic polymers can be used as coating materials, either 
alone or in combination, as a single or multi-layer coat, to achieve the taste 
masking by aqueous or organic based coating process [21, 22]. However, film 
coating may reduce the onset of action of the drug by retarding disintegration of 
the tablet and therefore the release of drug is affected. And usually high coating 
weight is demanded to achieve a satisfactory taste, especially for particle 
coating. 
(b) Granulation 
Mixture of bitter medicaments and sweeteners, hydrophobic polymers, lipids or 
waxes can be processed by dry, wet and melt granulation techniques to prepare 
taste masked oral solid or liquid dosage forms [23-25]. Taste masked 
pharmaceutical granules, which can be formulated as dry syrup, suspension, 
conventional chewable or dispersible tablet are described. For example, 
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granulation of erythromycin with alginic acid was shown to enhance the mouth 
feel and acceptance of the bitter medicament [24]. 
Granulation is a relatively inexpensive rapid operation and an easily scalable 
taste masking technology. Low melting point waxes such as glycerol 
palmitostearate, glyceryl behenate and hydrogenated castor oil are commonly 
used ingredients in granulation to achieve taste masking effects. Both pH 
dependent and independent water insoluble polymers, especially, the swelling 
polymers such as microcrystalline cellulose (MCC) and polycarbophil have been 
employed. A swelling matrix phenomenon can reduce the overall diffusion of the 
bitter active compound. Thus, swellable polymers can give a better taste 
masking in granulation compared to non-swellable polymers. However, during 
granulation, particle coating may remain incomplete, as a result of which, 
suppression of bitterness may be incomplete.  
(c) Sweeteners 
Sweeteners are commonly used in combination with other taste masking 
technologies. They can be mixed with bitter taste medicaments to improve the 
taste of the core material which is prepared for further coating or may be added 
to the coating liquids [26, 27]. But sweeteners for taste masking are not often 
successful for strongly bitter or water soluble bitter drugs. 
(d) Microencapsulation 
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Microencapsulation is a valuable technique applicable to protect the materials 
from volatilizing, oxidation as well as to mask their unpleasant taste [28]. 
Microencapsulation processes are commonly based on the principle of solvent 
extraction or evaporation. However, modifications of other techniques such as 
phase separation (coacervation) and spray drying are also utilized for 
microencapsulation [29]. Spray congealing is another method of 
microencapsulation [30-33]. Low encapsulation efficiency and environmental 
concerns due to use of organic solvents are the main limitations for 
microencapsulation technology. 
(e) Taste suppressants and potentiators 
In general, the hydrophobic nature of bitter substances contributes greatly to 
their interaction with the bitter taste receptor sites. Lipoproteins are universal 
bitter taste blockers. Studies using animal models show that lipoproteins 
composed of phosphatidic acid and β-lactoglobulin inhibit the taste nerve 
responses to bitter substances without affecting those due to the sugars, amino 
acids, salts or acids [34]. 
Potentiators increase the perception of the sweeteners taste and mask the 
unpleasant taste. Potentiators such as thaumatine, neohesperidine 
dihydrochalcone (NHDC) and glycyrrhizin can increase the perception of 
sodium or calcium saccharinates, saccharin, aspartyl-phenyl-alanine, 
acesulfame, cyclamates, and stevioside. Thaumatine was used with sugar 
alcohols to achieve the taste masking of bromhexine [35]. 
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(f) Solid dispersions 
Specific interactions between poorly soluble drugs and hydrophilic polymers can 
increase the drug solubility ; likewise specific interactions between the drug and 
the hydrophobic polymers can decrease the solubility of a drug [36].  
Solid dispersion was prepared from a solution of quinolone and the natural 
hydrophobic polymer shellac by solvent evaporation [37]. Solid dispersion of 
cephalosporins and cellulosic or methacrylic polymer was formulated to mask 
the unpleasant taste of the medicament. Additional excipients such as 
meglumine and magnesium silicate were added to increase the efficiency of 
taste masking [38]. Hydrophobic polymers and long chain fatty acids have been 
used to achieve the taste masking by solid dispersion. However, this approach 
usually requires a higher concentration of excipients compared to the other 
taste masking techniques. 
(g) Ion exchange resins  
Ion exchange resins are high molecular weight polymers with cationic and 
anionic functional groups. Resins form insoluble resinates with oppositely 
charged drugs maintains the low concentration of free drug in a suspension 
through weak ionic bonding. Chlorpheniramine maleate:Indion-234 (cation 
exchange resins) inclusion of ratio 1:2 was used to mask the bitter taste of 
Chlorpheniramine maleate [39-42]. But this method is not effective for acid 
drugs and delayed onset of action. 
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(h) Viscosity enhancers 
Suspending coated particles or microcapsules may not be efficient enough to 
achieve the taste masking of highly bitter medicaments in liquid oral 
suspensions. Usage of viscosity enhancers in these cases would retard the 
migration of dissolved medicament from the surface of the solid particle to the 
suspending medium. Additionally, they can also decrease the contact between 
the bitter medicament and the taste receptors, thus improving the overall taste 
masking efficiency [43]. At the same time, viscosity enhancers could prolong 
bitter aftertaste because of increased viscosity. 
(i) Complex formation  
Inclusion agents have been utilized to mask the objectionable taste of drugs. 
The mechanism of taste masking by inclusion formation has two theoretical 
possibilities. Either the cyclodextrins includes the bitter tasting molecule to 
inhibit its interaction with the taste buds, or it interacts with the gatekeeper 
proteins (GPCRs) of the taste buds [44-48]. However, whether the cyclodextrins 
can mask unpleasant taste of drug is dependent on the physicochemical 
properties of drug; additionally this approach requires cyclodextrin pre-inclusion 
formation of the drug before dosage form development. 
(j) pH modifiers  
Agents that can modify pH are capable of generating a specific pH 
microenvironment in aqueous media that can facilitate in situ precipitation of the 
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bitter drug substance in saliva thereby reducing the overall taste sensation for 
liquid dosage forms, e.g. suspensions. L-arginine maintains alkaline pH of the 
suspending vehicle to promote in situ precipitation of des-quinolone in saliva 
[49]. As for pH independent drugs, pH modifiers could not precipitate drugs for 
taste masking. 
(k) Adsorbates 
Adsorbates are commonly used with other taste masking technologies. The 
drug may be adsorbed or/and entrapped in the matrix of the porous component, 
which may result in a delayed release of the bitter active during the transit 
through the oral cavity thereby achieving taste masking. Kashid et al developed 
a taste masked pharmaceutical composition suitable for oral solid dosage form 
comprising adsorbate of unpleasant tasting active pharmaceutical agents and 
water insoluble polymer. In this technique, the active ingredient was blended 
with an adsorbent such as magnesium aluminium silicate to achieve the taste 
masking of bitter drug. The resultant blend was further granulated with water 
insoluble polymer to strengthen the taste masking without affecting the release 
of drug [50]. However, a higher concentration of adsorbates is needed, which is 
not beneficial to the final formulations. 
Although, various technologies have been developed to address the unpleasant 
taste of drugs, taste masking of pharmaceuticals can still be a challenge due to 
their limitations described above. Properties such as solubility, viscosity, pH, 
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coating weight and amount of excipient of drugs and excipients are often 
investigated empirically to design a taste masking formulation. Few studies 
attempt to predict whether the interactions level between API and their taste 
masking ingredients will result in bitter taste masking. As for cyclodextrins, the 
ring structure can have 6 (α-cyclodextrins), 7 (β-cyclodextrins), 8 (γ-
cyclodextrins) or more glucopyranose units connected by α-glycosidic bonds. A 
historical voyage from the discovery of these compounds in 1891 up to their 
present applications has been recently reported[51]. Due to the chair 
conformation of the glucopyranose units in the CD rings, they have the shape of 
a truncated cone or torus with the primary and secondary hydroxyl groups 
orientated to the narrow rim and to the wider edge of the cone, respectively. 
The CDs present then a hydrophilic external surface and a relatively lipophilic 
cavity in which guest molecules can be hosted. Ono and others measured the 
effects of parent CDs as well as the β-CD derivatives on the bitterness of a 
range of antihistaminic drugs. They showed that the level of bitterness 
suppression was correlated with the CD/drug binding coefficient K. A higher 
value of K means a lower free bitterant concentration and hence less bitter taste 
[46]. However, a few exceptions have been reported to the relationship between 
binding and bitterness reduction. Despite formation of a CD-caffeine inclusion 
[52], Gaudette and Pickering hardly observed any suppression of caffeine 
bitterness. Homoeriodictyol sodium salt reduced the bitterness of high and low 
caffeine by 15% and 43%, respectively. Meanwhile, the β-CD did not 
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significantly affect bitterness ratings, although interestingly, it trend towards an 
increase in bitterness [53]. In another example, the bitterness of propantheline 
and oxyphenonium bromide was more effectively suppressed by α- and γ-CDs 
than by β-CD [54] even the affinity of oxyphenonium bromide for CDs increased 
in the sequence β > γ > α [55]. Therefore, other factors might influence the taste 
masking of CDs for drugs. 
 
Approaches to evaluate and characterize taste masked products have resulted 
in the development of a number of quantitative/semi-quantitative methodologies: 
(a) Human taste panel test 
The human taste panel test is the main method used to establish the overall 
palatability and acceptability of a drug product to a patient towards the end of 
the development of an orally administered medicine. However its uses are 
restricted by ethical and safety concerns especially when testing drugs with 
limited toxicity data [56, 57]. 
(b) Electronic taste sensors  
There are several electronic sensors in the food and beverages industry using 
different measurement principles such as voltammetry, potentiometry, 
impedance, optical techniques and mass change [57]. The most commonly 
used in the pharmaceutical industry for taste evaluation is an electronic taste 
sensing system (electronic tongue). According to the definition of the IUPAC 
(International Union of Pure and Applied Chemistry) technical report, the 
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electronic tongue represents a multisensory system, which consists of a number 
of low selectivity sensors and uses advanced mathematical procedures for 
signal processing based on pattern recognition (PARC) and/or multivariate 
analysis [58]. Compared to the enormous amount of chemically different bitter 
substances, the number of electrodes (i.e., sensors) is limited. Thus, electronic 
tongues need to be cross-selective, which means not specific for a particular 
substance but universal to various bitter substances [59]. However, for a 
particular target, sensors with unique selectivity may be more useful [60]. With 
the development in selectivity and sensitivity, the electronic tongue becomes a 
promising instrument in bitterness evaluation and is an ideal alternative due to 
the lack of safety issues compared with human panel tests [61, 62]. Several are 
available including (i) SA401, SA402/TS-5000z (Insent, Atsugi-Chi, Japan) 
based on lipid membrane sensors; and (ii) a-Astree e-sensor (Alpha M.O.S., 
Toulouse, France) based on chemical modified field effect technology 
(ChemFET) with polymeric sensors. The Insent electronic sensor has detectors 
(exact composition is undisclosed by the manufacturer) assigned to a specific 
taste with partial cross-selectivity (e.g., AAE for umami, CT0 for saltiness, CA0 
for sourness, AE1 for astringency and AC0, AN0 and C00 for bitterness). The α-
Astree electronic taste sensing system (Figure 3) is a potentiometric based 
system with a seven-sensor probe and an Ag/AgCl reference electrode. The 
seven-sensor probe can differ in composition of different sensors [63]. These 
sensors operate in a cross-selective way and not assigned to a specific taste 
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quality or gustatory feeling. The underlying sensor technology is based on 
ChemFET, similar to the ion selective field effect technology (FET) technology, 
but sensors are coated with specific materials. These ChemFET sensors are 
composed of two highly conducting semiconductor regions surrounded with an 
insulator: a source and a drain. A sensitive layer (coated membrane) is 
deposited between the source and the drain. The type and composition of 
materials in the layer is not disclosed, but they are able to form specific 
interactions, like hydrogen bonds and van der Waals interactions with the 
chemical substances measured. 
 
Figure 3 Commercially available electronic tongues: α-Astree2 (AlphaMOS, 
Toulouse, France). 
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Data from sensor response (relative value mV or aftertaste sensor output (CPA), 
Euclidean distances) can be correlated directly with human taste panel data. 
Good correlation between taste data obtained using electronic sensor (Insent 
and Astree) and human taste data can be achieved [64-66]. 
(c) Drug release and dissolution test 
The measurement of the amount of drug released or dissolved in simulated oral 
cavity conditions can give an idea about the drug taste. The drug molecules 
must be dissolved in order to interact with the taste receptors in the (human) 
taste buds. Dissolution and release of APIs from a taste masking formulation is 
widely used to predict or quantify the in vitro effect of the taste masking 
technique. The most common choice as a medium is phosphate buffer (pH 6.8) 
as described in pharmacopeias [67-71]. Phosphate buffer with pH values in the 
range 5.6–8.0 has also been employed [72, 73]. Release into water (pH 1.5 and 
6.8) has also been used as a dissolution media in the evaluation of polymeric 
microparticles, where ‟tap water‟ was used to simulate intake conditions [74]. 
This was coupled with different taste masking evaluation methods such as 
human taste testing panels [75, 76]. The most common bias in these studies 
are: (i) the use of larger dissolution medium far exceeding normal human saliva 
volume; (ii) uncontrolled pH for example, use of water as dissolution medium; 
and (iii) filtration of sample and/or online analytical method are not used. 
(d) Animal models for taste evaluation 
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Some animal models are designed to measure the taste quality of a compound 
defined as the sense by which the qualities and flavour of a substance are 
distinguished by the taste buds (e.g., bitter, salty, sweet, umami and sour): 
these models are classified as „taste discrimination experiments‟. Alternatively, 
studies of „taste-guided‟ behaviour can assess the palatability of tastants 
defined by the overall appreciation of a substance by organoleptic properties 
such as vision, smell, taste, aftertaste and mouth feel (e.g., good or bad taste 
and aversiveness). Animal models such as the conditioned taste aversion 
(CTA), the operant taste discrimination, the high-throughput taste assessment 
model using 96-well plates, two bottle taste preference test and the brief-access 
taste aversion (BATA) model have shown promising results for identifying bitter-
tasting compounds [77].  
In the CTA models, the rats are presented with a reference taste (conditioned 
stimuli), which becomes associated with an aversive stimulus such as 
peritoneal injections of lithium chloride (LiCl). As a consequence, when the rat is 
exposed to novel compounds with a similar taste they will avoid it as a function 
of their similarity to the conditioned stimuli [78]. The operant taste discrimination 
model is an animal model where rats are trained to perform a specific 
behavioural task such as pressing a lever after having tasted a certain 
compound and an alternative task after sampling another tastant that can be 
distinguished from the first one [79]. When a novel tastant is presented to the 
animal, it will perform the task learnt depending on the degree of similarity of the 
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new compound to the two compounds learnt. In the high-throughput taste-
assessment model, rats are trained to sample different tastants in a standard 
96-well plate, and then perform an operant discrimination task: pressing levers 
to deliver food pellets [77]. In this method, taste quality is assessed by the taste-
discrimination component, whereas palatability is evaluated by the licks 
recorded from the 96-well plate. In the two-bottle taste preference experiment, 
animals have free access in their cage to two different bottles, one containing a 
taste solution and the other containing water or a different taste solution. This 
test is usually 48 h in duration to assess a single concentration. After 24 h, the 
relative positions of the two bottles are counterbalanced because rodents can 
have pronounced side preferences. The volume missing from each bottle is 
measured and a preference ratio of tastant to water then calculated [80]. In the 
BATA model, rodents, most often mice or rats, are mildly water deprived for a 
period of 16–24 h to motivate them to drink. The rodents are then put into an 
apparatus called a lickometer, which records the number of licks that the 
rodents make to different concentrations of the compound under test samples 
presented in several sipper tubes. Animals only have a very short period of time 
(between 5 and 10 s) to sample a solution. Typically, a high number of licks 
indicate a pleasant taste whereas when licks are nearly completely suppressed 
it indicates an unpleasant taste. 
However, these methods are not able to directly investigate the fine 
microstructures or molecular distribution of taste masking products within a 
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formulation before and after release of the API/taste masking ingredients. 
Therefore, a quantitative method to correlate the detailed structural information 
with the drug release behaviour will provide mechanism and novel knowledge 
for taste masking technologies. 
With respect to the challenges of taste masking the focus of the present 
investigation was on the molecular basis and microstructure basis of bitter taste 
suppression: 
(1) To investigate the molecular basis of bitter taste suppression Surface 
Plasmon Resonance Imaging (SPRi) and High Performance Affinity 
Chromatography (HPAC) where used to construct a database of  Ka and Kd 
values determined from the inclusion of bitter drugs with hydroxypropyl-β-CD 
(HP-β-CD) and correlating this with bitter taste masking data from  electronic 
tongue measurements.  Principal component analysis (PCA) from electronic-
tongue data was used to quantitate the relationship between bitter taste 
masking by HP-β-CD. Specifically, the Euclidean distance (D) between each 
drug and its corresponding HP-β-CD inclusion complex as measured by the 
electronic tongue taste sensor apparatus. In this way a model based on 
molecular kinetic parameters and D (using SPSS, a software package used 
for statistical analysis acquired from IBM) was established to investigate the 
relationship between host-guest kinetics of CD-drug interactions and taste 
masking. Furthermore, a kinetic model of CD-drug inclusion was applied for 
producing a formulation with optimal taste masking properties. 
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(2) To investigate the formulation microstructure basis of bitter taste supression 
Synchrotron Radiation-based Micro Computed Tomography (SR-μCT) was 
utilized to investigate the relationship of the fine microstructure of formulated 
microspheres and mechanism of taste masking. The formulation approach 
adopted was the technique of layer-by-layer coating onto lipid microspheres 
for taste masking and Synchrotron Radiation-based Fourier-transform 
Infrared (SR-FTIR) used to determine the distribution of the formulation 
components on the cross section of microspheres and film coating. Thus the 
SR-μCT and SR-FTIR provided a deep understanding of the nature of the 
fine microstructure of taste masking formulations and their structural 
assembly in microspheres. This approach facilitated rational design and 
manufacturing of taste masking products. 
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Chapter 2 Relationship between Host-Guest 
Kinetic of Drug-CD Interactions and Taste 
Masking 
 
Inclusion agents have been utilized to mask the objectionable taste of drugs. 
Cyclodextrin (CD), a cyclic oligosaccharide derived enzymatically from starch 
hydrolysylates, is an inclusion agent for food and drugs which has been 
approved by the FDA [81, 82]. The best-characterized forms are α-CD and β-
CD consisting of six and seven D-glucose units, respectively. α-CD and β-CD 
are widely accepted ingredients for taste masking with relatively good solubility 
in water [83-85]. The CD molecule possesses a tapered cone structure with an 
inner diameter of 5-10 Å which can accept a wide range of molecules into a 
hydrophobic cavity to form a thermodynamically stable inclusion [86]. 
Amphiphilic molecules can be partially entrapped by CDs with the hydrophobic 
moiety within the cone cavity and the hydrophilic portion excluded and hence 
within the solvent phase. The bitter taste could be suppressed if the molecular 
component of the bitter tasting drug is partially or totally concealed within the 
CD cavity. The binding affinity of CD to a given compound is usually 
represented by a binding equilibrium coefficient (K). The K values for drugs and 
small molecules have been reported to be relatively weak in the range of 10-3-
10-6 M-1 [87, 88]. In a study of aromatic compounds, Astray et al. showed K was 
lower for α-CD than for β-CD (i.e., the larger diameter cone could bind more 
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efficiently) and increased linearly with logP (i.e., more hydrophobic compounds 
were bound more readily) [89]. The effect of parent CDs and β-CD derivatives 
on a range of antihistamines showed bitter taste suppression was correlated 
with the drug/CD binding coefficient K. [46]. However, some exceptions have 
been reported to the expected relationship between binding and bitterness 
reduction. Despite the formation of a strong CD-caffeine inclusion [52], poor 
suppression of caffeine bitterness by CD inclusion was observed [53]. In 
another example, the bitterness of propantheline and oxyphenonium bromide 
was effectively suppressed by α-CD and γ-CD more than β-CD [54]. The affinity 
of oxyphenonium bromide for CDs increased in the sequence β > γ > α [55]. 
Therefore, other factors might also influence the taste masking capability of 
drugs by CDs, such as the host-guest kinetics of the association (Ka) and 
dissociation (Kd) processes, which is the basis for the inclusion formation [86, 
90, 91]. 
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where, Ka was the association rate constant and Kd was the disassociation rate 
constant. 
Additionally, besides formation of CD inclusion, bitterness might be suppressed 
if molecular groups responsible for the bitterness could be competitively bound 
by groups outside the CD ring with bitter receptor on taste bud. Therefore, the 
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relationship between taste masking effects and host-guest interaction between 
CDs and drugs should be investigated more deeply.  
However, the quantitative measurement of kinetics constants has proved 
challenging [92-94] due to short relaxation time (< 1 s) and high time of 
resolution which is difficult to achieve [95]. The use of fluorescence correlation 
spectroscopy, capillary electrophoresis, isothermal titration calorimetry, NMR 
spectroscopy and high performance affinity chromatography to determine 
kinetics constants is limited due to the poor reproducibility and/or labour 
intensive procedures [96-98]. Recently, we have reported high-throughput 
methodology based on the conjugation of small molecule microarray and SPRi 
for the measurement of drug-CD kinetic constants [99]. 
Surface plasmon resonance is a charge-density oscillation that may exist at the 
interface of two media with dielectric constants of opposite signs, for instance, a 
metal and a dielectric. The charge density wave is associated with an 
electromagnetic wave, the field vectors of which reach their maxima at the 
interface and decay evanescently into both media. This surface plasma wave 
(SPW) is a TM-polarized wave (magnetic vector is perpendicular to the direction 
of propagation of the SPW and parallel to the plane of interface) [100]. SPR 
transduction belongs to the class of refractometric sensing devices, which use 
evanescent waves to investigate surface phenomena. Changes in refractive 
index at the sensing surfaces due to analyte binding influence the resonant 
angle and this shift is used to generate a real-time signal. In contrast to 
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scanning angle SPR, SPRi systems are generally based on intensity modulation, 
measuring the reflectivity of monochromatic incident p-polarised light at a fixed 
angle. SPRi offers two main advances over conventional SPR: the ability to 
visualise the entire biochip surface in real time and the chance to monitor up to 
hundreds of molecular interactions continuously and simultaneously in a multi-
array format of molecular probes formed as circular or square spots. It is also 
possible to control the quality of the spotted array by viewing the surface image 
to accurately select the measurement area. The ability to immobilise many 
receptors (up to hundreds) on the surface and to monitor the kinetic parameters 
of biospecific interactions simultaneously, in a real-time and label-free 
microarray format, is a tantalising opportunity. Spots (currently from 50_m2 up 
to 1 cm2) can be created both manually or by automatic spotters [101]. 
Using a SPRi database, Ka and Kd values, determined from the inclusion of 13 
bitter drugs with HP-β-CD, were correlated with bitter taste masking data from 
the electronic tongue (model/manufacturer). An electronic-tongue was used to 
quantitate the bitter taste masking by HP-β-CD, specifically the Euclidean 
distance (D) between drugs and its corresponding HP-β-CD inclusion based on 
the PCA of the electronic tongue taste sensor data. In this way a model based 
on Ka, Kd and D by SPSS software was established. The reliability of the 
established model was verified by 10-fold cross-validation and then used to 
predict the extent of taste masking of 44 bitter drugs by HP-β-CD. 
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2.1 Modelling and Prediction of Taste Masking by Host-
Guest Kinetic of Drug-CD Interactions Measured by 
SPRi 
A variety of bio-interactions have been reported on SPRi for measuring protein-
ligand interaction and protein–protein binding [102-105]. The performance and 
efficiency of SPRi are mainly dependent upon the surface chemistry. A small-
molecule microarray screening platform based on a surface with high sensitivity 
and immobilization capacity which is able to detect weak interactions in the 
micromolar range [97]. The photo-cross-linked technique with surface initiated 
polymerization (SIP) chemistry proved to be highly efficient for screening of 
thousands of molecules on a single platform.  
2.1.1 Materials 
Caffeine, Chloramphenicol and Norethindrone with purity of 99.0%, Metoprolol 
tartrate salt and Ofloxacin with purity of 98.0% were purchased from Shanghai 
Suobio Bioscience & Technology Co. Ltd., China. Theophylline, Ethosuximide 
and Orphenadrine hydrochloride with purity of 98.0% were purchased from 
Tokyo Chemical Industry Co. Ltd., Shanghai. Theobromine and Penicillamine 
with purity of 99.0% was supplied by Sinopharm Chemical Reagent Co., Ltd., 
China. Propranolol hydrochloride with purity of 100% was provided by National 
Institute for Food and Drug Control, China. Cortisone with the purity of 99.0% 
was purchased from Merck Co., Inc., USA. Nortriptyline hydrochloride with 
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purity of 98% was obtained from Sigma-Aldrich Co. LLC. HP-β-CD (degree of 
substitution = 4.5, substituent groups per glucopyranose unit) was obtained 
from Shijiazhuang Pharmaceutical Group Co., Ltd., China. 
2.1.2 Methods 
2.1.2.1 Kinetic constants determination by SPRi 
The SIP surface was prepared according to our previously published work [106]. 
In brief, a mixed self-assembled (SAM) solution was prepared by initiators ω-
mercaptoundecyl bromoisobutyrate (BrC(CH3)2COO(CH2)11SH) and EG3-thiol 
in a 1:99 ratio. The sensor chips CM5, purchased from GE Healthcare UK 
Ltd.(Buckinghamshire, England), were immersed in this mixture (1 mM total 
concentration) for 16 hours at room temperature, and then thoroughly washed 
by ethanol and Milli-Q water and dried in a nitrogen stream. The polymerization 
solution was prepared by 64 mg Bipy, 10 mL 0.04 M CuCl2, 2.6 g HEMA, 7.2 g 
OEGMA, 20 mL Milli-Q water and 20 mL methanol. After 30 min deoxygenation, 
10 mL of Ascorbic acid (0.04 M) were added to the solution and the chips were 
immersed in this solution for 16 hours at room temperature under an 
atmosphere of nitrogen. After being thoroughly washed with methanol and Milli-
Q water, the chip were incubated in a DMF solution containing 0.1 M N,N‟-
disuccinimidyl carbonate and 0.1 M dimethyl amino pyridine (DMAP) for 16 
hours for acidification [107]. 
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The photo-cross-linker moiety (3-trifluoromethylene-diazarine) was synthesized 
according to a previously reported protocol by Kanoh et al [108]. PEG and SIP 
assembled slides were activated by a freshly prepared aqueous mixture (1:1) of 
EDC/NHS solution for 20 minutes. Slides were then incubated with a 100 mM 
base added (500mM diisopropylethylamine) solution (DMF) of photo-cross-
linker (20 mL), covered with cover slips and placed in the dark for 4 hours at 
room temperature. Slides were then extensively washed with DMF for 30 
minutes and blocked with a 1 M solution of ethanolamine in DMF. After washing 
with DMF and ethanol (10 minutes) and drying with N2, the slides were ready for 
printing. Stock solutions (10 mM) in 100% DMSO were spotted in multiplex 
using a Genetix QArray 2 spotter (produced 300 mm features) and left for 
complete evaporation of DMSO (under vacuum) at room temperature for 2 h. 
After printing, the slides were exposed to UV irradiation 2.4 J cm-2 (365 nm) in a 
UV chamber (Amersham life science). The slides were subsequently washed 
with DMSO, DMF, ACN, ethanol, phosphate buffered saline (PBST) and finally 
with distilled water for 30 minutes (ultrasonically), respectively, to remove non-
covalently bound compounds. Dried slides were assembled with a flow cell and 
then mounted on the SPRi instrument for measurement. 
All the experiments were carried out using the PlexArray® HT system (Plexera, 
LLC) which is based on surface plasmon resonance imaging [109]. All samples 
were injected at the rate of 2 μL·s-1 and 25 oC. Oval regions of interest (ROIs) 
were set as a 9 pixel × 7 pixel area in imaging area. ROIs of bovine serum 
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albumin (BSA) were used as controls for the measurement of specific signals. 
CDs solutions in PBST containing Tween 20 (0.05%), pH 7.4 were used as 
analytes with an association and dissociation flow rate of 2 μL·s-1 at different 
concentrations by serial dilution. A solution of glycine·HCl (pH 4.2, 0.05M) was 
used to regenerate the surface and remove bound proteins from the small 
molecules enabling the sensor chip to be reused for additional analyte injections. 
HP-β-CD solutions were flowed at multiple concentrations (0.25, 0.5 and 1 mM) 
over a small molecule microarray containing 485 compounds on a single slide 
as described previously [99]. The average value of the kinetic constants was 
calculated by using Plexera SPRi data module software. Detailed kinetic 
parameters including Ka, Kd and K of 485 drugs against HP-β-CD were 
calculated (see Appendix), 57 of which were recorded as bitter drugs as per 
United States Pharmacopoeia 36 (2013). 13 drugs were selected as a test set 
in accordance with the range of Ka and Kd values which uniformly distributed 
and covered as many other bitter drugs as possible, for the current research 
purpose (Table 1). 
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Table 1 The Ka, Kd and K determined by SPRi for thirteen model bitter drugs as 
test set 
Drugs Ka (1/Ms) Kd (1/s) K (1/M) 
Caffeine 72.1 3.43E-05 2.10E+06 
Chloramphenicol 3310 1.23E-04 2.69E+07 
Cortisone 574 1.74E-06 3.30E+08 
Ethosuximide 2280 2.30E-05 9.91E+07 
Metoprolol 1520 2.31E-05 6.58E+07 
Norethindrone 502 1.27E-05 3.95E+07 
Nortriptyline  2370 1.00E-04 2.37E+07 
Ofloxacin 530 5.47E-05 9.69E+06 
Orphenadrine  1520 6.38E-05 2.38E+07 
Penicillamine 3900 8.29E-05 4.70E+07 
Propranolol  512 9.83E-05 5.21E+06 
Theobromine 3420 4.57E-05 7.48E+07 
Theophylline 273 6.03E-05 4.53E+06 
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2.1.2.2 Electronic tongue test 
13 bitter drugs were selected for testing bitterness using an automated 
electronic tongue (α-Astree electronic tongue gustatory system (Alpha M.O.S., 
Toulouse, France)). Seven specific sensors, i.e., ZZ, AB, GA, BB, CA, DA, and 
JE, were used. Each sensor is configured in a silicon transistor and has a 
specific organic membrane that interacts with ionic, neutral, and chemical 
compounds present in the sample solution in a specific manner. Any interaction 
at the membrane interface is detected by the sensor and converted into an 
electronic signal. The potentiometric difference between each of the seven 
sensors and the Ag/AgCl reference electrode at ambient temperature was 
measured for each compound with a data acquisition time for each sample of 
120 s. The electronic tongue approach has been shown to provide data which 
correlate well with results from a human taste panel study [110-112]. 
Samples measurements were replicated at least eight times and the mean 
values and standard deviation were determined from the last three 
measurements. The first three replicate measurements of the test solution were 
for sensor training purposes. Following each analysis, the sensors were rinsed 
in deionized water for 10 s to prevent cross-contamination between samples or 
carry-over residues from previous samples. 
Drugs were dissolved with deionized water to a concentration of 1 mM. The 
hydrophobic drugs were dissolved into ethanol (1 mL) followed by dilution with 
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deionized water in volumetric flasks (100 mL) to the same concentration. The 
taste and odour of ethanol at the concentration of 0.01 g/L was not 
discriminated from deionized water [113]. The drug-HP-β-CD inclusion solution 
was mixed and prepared at 1:1 molar ratio. The solutions were filtered through 
a Millipore filter paper (0.45-μm) to prevent particulate damage to the α-Astree 
sensors. Taste analysis of drug-HP-β-CD inclusion was carried out by electronic 
tongue. 
The signals of the sensors after each assay were integrated into a data matrix 
that was computed by multidimensional statistic tools. Taste maps of tested 
samples based on PCA were generated using all sensors. PCA [114] is a well-
established statistical method for dimensionality reduction and has been widely 
applied in data compression, image processing, exploratory data analysis, 
pattern recognition, and time series prediction [115]. PCA involves a matrix 
analysis technique called eigenvalue decomposition. The decomposition 
produces eigenvalues and eigenvectors representing the amount of variation 
accounted for by the principal component and the weights for the original 
variables, respectively. The main objective is to transform a set of correlated 
high dimensional variables to a set of uncorrelated lower dimensional variables 
(principal components). Therefore, PCA was utilized to convert the seven-
dimensional data set obtained from seven different taste sensors to two-
dimensional data for the ease of data analysis. Essentially, this approach 
summarizes the information contained in the database into individual principle 
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components, which are linear combinations of the original variables. For every 
sample analysis, the two principle components with the most informative results 
were used to create the PCA map. In the PCA maps, data points of the samples 
were compared using the calculated distance between them. The distances 
between the drug and drug-HP-β-CD inclusion represented the difference or the 
similarity between the taste of drug and that of drug-HP-β-CD inclusion, which 
indicated the magnitude of the taste masking effect of CD on specific drugs. If 
the distance of the sensor output value between drug and drug-HP-β-CD 
inclusion is small, the taste of the drug sample resembles that of the drug-HP-β-
CD inclusion indicating poor taste masking effect. 
2.1.2.3 Modeling 
Based on Ka and Kd of each drug measured by SPRi, 12 derivative parameters 
(Ka, Kd, Ka
2, Ka
3, KaKd, Ka
2Kd, KaKd
2, Ka
3Kd, KaKd
3, Kd
2, Kd
3, Ka/Kd) were 
calculated as independent variables. Before undertaking the modeling process, 
these parameters were normalized (divided by maximum value) in consideration 
of the difference of dimension and units between Ka and Kd. Euclidean distance 
between drug and corresponding drug-HP-β-CD inclusion were used as 
dependent variables for modeling. 
In addition, data from the 13 bitter tasting model compounds were used to 
construct a statistical model of kinetic parameters versus taste-masking using 
SPSS statistics software (version 19.0). Independent variable reduction and 
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model construction were carried out by stepwise linear optimization of the 
regression line fit as determined by R2 and P values.  
2.1.2.4 Cross-validation and prediction 
In order to check if the model was sensitive to the presented data sets and 
correctly predict the outcome using other data sets, a 10-fold cross validation 
technique was used to evaluate how the results of the statistical analysis would 
generalize to an independent data set. The data set was divided into 10 folds 
and one of the 10 subsets was used as the test set, whilst the other 9 subsets 
were put together to form a training set. This technique has a lower variance 
compared to other methods and can be used to check if the model is over-fitting. 
The established model was used to predict CD-drug kinetic values for another 
44 bitter drugs in the established SPRi database. The Ka and Kd values of the 
44 drugs provided data for the developed equation to calculate the predicted 
distances.  
2.1.3 Results and discussion  
2.1.3.1 Taste evaluation by the electronic tongue 
The relative standard deviations of the three measurements taken for each 
sample were less than 2%, indicating high accuracy and repeatability of the 
sensor data. The taste sensor data generated from the electronic tongue was 
analyzed using PCA and based on the statistical analysis for the determination 
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of Euclidean distance between drug and its corresponding HP-β-CD inclusion. 
The PCA map (Figure 4) with two-dimensional data represented almost 100% 
of information on its two axes without any loss.  
 
Figure 4 PCA map of bitter drugs and corresponding drugs-HP-β-CD inclusions 
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The bitter taste intensities of 13 drugs were different from each other. Therefore, 
the Euclidean distance is indicative of how close/far the taste of two samples is 
relative to each other. In other words, the degree of taste masking of a drug by 
CD is greater when a longer Euclidean distance is measured between the drug 
and its corresponding HP-β-CD inclusion. After adding HP-β-CD, the locations 
of all HP-β-CD-drugs moved to the right compared with drugs. The further HP-
β-CD-drugs moved the better taste-masking effects should be obtained. The 
Euclidean distances for each sample pair are shown in Table 2. Among the 13 
drugs, the distance of norethindrone was the shortest, demonstrating that its 
taste was relatively the most difficult to be masked by HP-β-CD. It is believed 
that large molecular size of norethindrone (7.2 Å, shortest linear dimension of 
the three dimensional molecule) makes it difficult to fit into the hydrophobic 
cavity (6-6.5 Å) of HP-β-CD. Although the molecular weight of nortriptyline 
(263.38) is similar to norethindrone (304.47), the hydrophobic branched 
alkylamino side chain, which might be responsible for the bitterness in 
nortriptyline structure [116], is of a size and lipophilicity that makes it able to fit 
into the hydrophobic region of HP-β-CD. Based on this data, the taste masking 
effect of nortriptyline-HP-β-CD inclusion was the best amongst the 13 tested 
model drugs. 
 
 
  35 
Table 2 Taste masking effect (Distance) of thirteen model bitter drugs 
Samples Solubility (mg/mL) Distance 
Caffeine 58 143 
Chloramphenicol 1.1 253 
Cortisone 0.14 46 
Ethosuximide 41 279 
Metoprolol 11 112 
Norethindrone 0.030 43 
Nortriptyline 0.066 385 
Ofloxacin 0.069 76 
Orphenadrine 0.30 335 
Penicillamine 31 217 
Propranolol 0.47 58 
Theobromine 9.7 185 
Theophylline 13 128 
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2.1.3.2 Modeling 
By stepwise regression for independent variable reduction, it was found that 6 
parameters derived from the Ka and Kd measured by SPRi exhibited marked 
influence on the taste masking effects of CD-drug inclusions, Ka
3, Kd, KaKd, Kd
3, 
Ka
2 and Ka/Kd were identified from twelve pre-set kinetic parameters. It is well 
known that the K (Ka/Kd) is one of the important factors for taste masking effects 
[89]. However, besides K, other parameters also contribute to the taste masking 
effects. 
Based on the six selected parameters, a multiple-linear regression model was 
established, as given in Eq. 3 with R2=0.96 and P≤0.05.   
314683825 004.3*1394589.2272.5266.2902.6 ddad
d
a
aa KEKKKE
K
K
EKEKED      (3) 
It is generally recognized that Ka and Kd should have positive and negative 
correlation with taste masking effects, respectively, since Ka reflects the rate of 
drug binding/inclusion and Kd reflects the rate of release of drug which is then 
available for bitter taste receptor binding. However, both of Ka
3 and Kd
3 showed 
a negative correlation with Euclidean distance, while other derived parameters 
had a positive correlation with taste masking effects, thus indicating a 
relationship involving additional factors between taste masking effect and kinetic 
parameters of drug-HP-β-CD. A three dimensional model for distance as a 
function of Ka and Kd was developed and is illustrated in Figure 5. 
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Figure 5 Three dimensional model constructed based on thirteen model bitter 
drugs (blue balls) for relationship between Ka, Kd measured by SPRi and taste 
masking effects of HP-β-CD on bitter drugs as measured by the electronic 
tongue 
From this model, it can be observed that the Euclidean distance data measured 
from electronic tongue evaluation of bitter tasting drugs rapidly increased when 
Kd was closed to zero, which indicated a strong drug-CD inclusion. Therefore, 
concentration of free bitter drug in the solution was too low to be measured. 
Additionally, in the three dimensional graph white zone of Ka < 1000 and Kd > 
0.0001, the Euclidean distance decreased to zero, which demonstrated that 
drugs located in this area did not form an effective drug-HP-β-CD inclusion to 
mask bitter taste. However, electronic tongue distance measurement rose to an 
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apogee then fell as Ka progressed from 0 to 4000. A similar trend in Euclidean 
distance rise and fall was observed as Kd progressed from 0 to 0.0001.  
Nevertheless, the model produced good correlations between taste masking 
effects and kinetic parameters of HP-β-CD, even with the relatively small 
number of test samples. However, the range of Ka and Kd covered by 13 model 
drugs represented more than 80% of drugs in the data base enabling good 
coverage of molecules that could undergo kinetic analysis to determine whether 
drug-HP-β-CD interactions predict bitter taste masking. 
2.1.3.3 Cross-validation and prediction 
This procedure was continued thirteen times, and one of the samples was 
considered as the test set at each time point. The cross-validation result was 
evaluated by correlation coefficient, which was calculated by Eq.4, 
)()(
),(
YDXD
YXCov
XY                                                                                         (4) 
where X was the predicted distance and Y was the determined distance. 
Cov(X,Y) was covariance of predicted distance and determined distance. D(X) 
and D(Y) were variance of predicted distance and determined distance, 
respectively. 
The correlation of determined Euclidean distance (Y) as a function of predicted 
distance (X) of each drug was calculated by 10-fold cross-validation (Figure 6). 
It is well known that two sets of data strongly correlate with each other when the 
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correlation coefficient is about 0.8 to 1. A strong correlation was obtained as 
given in Eq. 5 with a correlation coefficient of 0.84, P<0.05 (bivariate correlated 
analyse by SPSS). 
24.268737.0  XY                                                                                       (5) 
The slope of Eq.5 was close to 1 with an X/Y axis intercept close to zero, 
indicating that the established model possessed only small systematic errors 
and was sufficiently accurate to enable its application to predict the taste 
masking effect of HP-β-CD on the wider data base of bitter drugs.  
 
Figure 6 The correlation-ship of predicted distance versus determined distance 
for constructed model by 10-fold cross-validation  
Using Eq.3 the predicted distance of the additional 44 bitter drugs was 
calculated. The predicted Euclidean distances of 29 bitter drugs were circa 20-
300 (Table 3), illustrating that various degrees of taste-masking levels will be 
achieved using HP-β-CD. 
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Among the 29 drugs demonstrating predicted Euclidean distance above zero 
(Table 3), 8 drug-CD inclusions were confirmed to be bitter taste masked 
through inclusion with β-CD or HP-β-CD. It appears that bitterness of drugs with 
predicted distances larger than 100 were more likely to be masked by drug-CD 
inclusion. Although the reported drug-CD inclusions were of β-CD or HP-β-CD, 
the SPRi signal responses for each drug against β-CD and HP-β-CD were of 
the same order of magnitude and showed very similar trends of signal 
responses. This is possibly due to the same inner cavity and that the change in 
functional groups affects the interaction profile to a little extent [99]. Thus, the 
taste masking effects of these two chemical types of CDs also follow similar 
patterns (i.e. they resembled each other). The bitter taste of primaquine with 
predicted distance of 303, was effectively masked, which is in accordance with 
a literature report that the bitter taste of primaquine was completely inhibited by 
β-CD [117]. The alkyldiamino functionality of primaquine responsible for 
generating bitterness has a molecular size and lipophilicity predicted to undergo 
inclusion with β-CD. The bitterness of famtodine (predicted distance, 169) was 
partially masked by drug-CD inclusion and more effectively masked when 
forming a ternary complex with β-CD and HPMC [118]. The linear structure of 
famotidine incorporating sulfamoylpropanimidamide and diaminomethylidene 
functionality would likely lead to partial exposure of a bitter tasting moiety 
regardless of how famotidine was included within β-CD. Another similar 
example is seen for HP-β-CD inclusion in the 1:1 M ratio with 0.09% sodium 
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saccharin as optimum in masking the bitter taste of lidocaine [76, 119], with a 
predicted distance of 168. Of the additional 44 bitter drugs, the predicted 
distances of 15 drugs were zero or negative, indicating that not only is HP-β-CD 
ineffective for taste masking, but also there is possibly an inherent error in the 
model. For example, it was recommended by the FDA that the palatability of 
medicines containing chloroquine, an anti-malarial drug with strong bitterness, 
should be improved [120]. However, to date, there is no published literature or 
patent showing that the bitterness of chloroquine could be effectively masked by 
CD. It can be hypothesized that steric hinderance due to the halogen group of 
chlorobenzene interferes with  the formation of chloroquine  inclusion with CD or 
that the alkylamino side chain is not part of the CD-chlroquine inclusion complex 
allowing the tertiary amine to participate in bitter taste.  
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Table 3 Predicted distance of bitter drugs, for which the reported ones of taste masking by CD show tendency to have large 
predicted distance of taste masking by HP-β-CD 
Drugs Ka (1/Ms) Kd (1/s) 
Predicted 
Distance 
If Reported by Literature 
or Patented 
Taste Masking Effect 
Dapsone 61 9.04E-05 20 No / 
Prilocaine 434 2.92E-06 28 No / 
Antazoline  151 1.92E-05 54 No / 
Sparfloxacin 15.8 7.98E-05 56 No / 
Prednisolone 200 2.06E-05 60 Yes [121] Better than PEG 6000 
Vancomycin  242 2.87E-05 81 Yes [122] No details 
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Drugs Ka (1/Ms) Kd (1/s) 
Predicted 
Distance 
If Reported by Literature 
or Patented 
Taste Masking Effect 
Dicyclomine  39.3 7.05E-05 56 No / 
Bumetanide 636 5.73E-07 60 No / 
Hydroxychloroquine  303 3.10E-05 91 No / 
Antipyrine 88 5.07E-05 99 No / 
Carisoprodol 449 3.05E-05 102 No / 
Tramadol  238 6.78E-05 108 No / 
Pyridostigmine 497 3.37E-05 114 Yes [76] Acceptable taste masking effect 
Trifluoperazine  490 3.55E-05 117 No / 
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Drugs Ka (1/Ms) Kd (1/s) Predicted 
Distance 
If Reported by Literature 
or Patented 
Taste Masking Effect 
Cefoperazone 357 6.94E-05 122 No / 
Cefuroxime 1070 1.70E-05 122 Yes [123] 
Taste-masked by multi-
components with CD 
Sulfamethizole 395 7.18E-05 124 No / 
Propafenone  621 8.44E-05 133 No / 
Pentobarbital 1140 2.52E-05 159 No / 
Digoxin 1090 2.68E-05 159 No / 
Lidocaine 2260 1.31E-04 168 Yes [76, 119] Partially masked 
Famotidine 899 8.93E-05 169 Yes [118] Partially masked 
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Drugs Ka (1/Ms) Kd (1/s) 
Predicted 
Distance 
If Reported by Literature 
or Patented 
Taste Masking Effect 
Chlorpropamide 2720 1.97E-05 185 No / 
Praziquantel 1310 2.78E-05 186 No / 
Tetracaine 2040 2.56E-05 233 No / 
Isoniazid 2390 2.71E-05 244 No / 
Cetirizine 1790 3.16E-05 245 Yes [124] Better than maltodextrins 
Papaverine 1820 3.13E-05 246 No / 
Primaquine 1790 4.76E-05 303 Yes [117] Completely masked 
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2.2 Modelling and Prediction of Taste Masking by Host-
Guest Kinetic of Drug-CD Interactions Measured by 
HPAC 
With advantages of rapid speed, high precision and ease of automation, HPAC 
is another technique to measure the kinetics of interactions with weak to 
moderate affinities. Since 1980s, Hage‟s group has employed chromatographic 
techniques based on HPAC to study the kinetics of drug-human serum albumin 
(HSA) and antibody-antigen interactions [125-136].  
In chromatography, peak width increases in proportion to the square root of the 
distance that the peak has migrated. Mathematically, this is equivalent to saying 
that the square of the standard deviation is equal to a constant time the 
distance travelled. The height equivalent to a theoretical plate, as discussed 
above, is defined as the proportionality constant relating the standard deviation 
and the distance travelled. Thus, the defining equation of the height equivalent 
to a theoretical plate is as follows,  
HETP = σ2/L                                                                                                    (6) 
in which σ is the standard deviation and L the distance travelled. The use of the 
plate height is superior to the use of peak width in evaluating various 
chromatographic systems, because it is constant for the chromatographic run, 
and it is nearly constant from solute to solute. In a previous study [137], a 
modified peak profiling HPAC method based on the correction of the plate 
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height for the non-retained substance was established to determine the 
dissociation rate constant of paracetamol and sertraline-CD supramolecules. 
The apparent dissociation rate constants were estimated for paracetamol and 
sertraline respectively with multiple flow rates, which were in good agreement 
with the magnitude of the rate constants for other drugs determined by capillary 
electrophoresis reported in the literature [97]. The multianalyte approach was 
further developed to simultaneously measure the Kd values of three drugs 
through one injection based on the investigation of the dependence of drug-CD 
kinetics on the mobile phase composition (including the ion strength, the pH and 
the addition of the organic solvents) [138, 139]. It was demonstrated that for 
both of the single and multiple flow rate peak profiling methods, the Kd values of 
paracetamol, phenacetin and S-flurbiprofen determined by the multianalyte 
approach were statistically equivalent with that of the single compound analysis 
(p>0.05).  
The peak profiling method is a useful chromatographic tool to study the kinetics 
of drug/macromolecule reversible reactions. The theoretical derivation for this 
approach was first reported in 1975 by Denizot and Delaage [140]. In the peak 
profiling method, the retention times and variances were measured on an 
affinity column for both a retained solute and a non-retained substance using 
linear zonal elution. Initially, the peak profiling method was carried out at a 
single flow rate and the Kd was estimated as follows. 
2
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M
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

                                                                                       (7) 
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where, tR and σR
2 are the retention time and variance of the peak for the 
retained solute on an affinity column, while tM and σM
2 are the retention time and 
variance of the peak for the non-retained substance on the same affinity column. 
In Eq. 7, it was assumed that all sources of band broadening other than 
stationary phase mass transfer were either negligible or the same for the 
retained and non-retained species.  
A modified form of the peak profiling method at multiple flow rates was further 
developed [127-130], as shown in Eq. 8. 
2
d
MR
)(1K
2
k
uk
HH

                                                                                         (8) 
where, HR is the plate height of the retained solute on an affinity column, and 
HM is the plate height of the non-retained substance on the same column. The 
term k is the retention factor for the retained solute on the affinity column. The 
term u is the linear velocity of the mobile phase. The value of Kd can be 
determined by plotting (HR-HM) versus (uk)/(1+k)
2, which would result in a linear 
relationship with a slope inversely related to Kd. 
As described in previous studies [137-139], plate heights for theoretical non-
retained substances on the CD column could not be determined directly with 
conventional non-retained substances due to the extensive inclusion of a wide 
variety of ions and molecules by CDs, even the usual so-called non-retained 
void volume indicators. Thus, a correction of plate heights for conventional non-
retained substances (HM,C) has been made to estimate plate heights for 
theoretical non-retained substances (HM,T) (Eq. 9), and then the Kd of drugs on 
β-CD columns could be determined according to Eq. 8.  
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where, λ is the correction factor, AC and BC are the A-term and B-term for the 
conventional non-retained substance, respectively. The λ can be calculated 
from the ratio of the B-term for the theoretical non-retained substance and that 
for the conventional non-retained substance, Csm,T is the stagnant mobile phase 
mass transfer related C-term for the theoretical non-retained substance. 
For the comprehensive determination of Ka, Kd and K values by 
chromatography, K can be efficiently measured by the peak fitting method in 
zonal elution with high sample concentrations according to Hage‟s report [141]. 
As shown in Eq. 10, the nonlinear chromatography (NLC) model derived from 
impulse input solution can be used to calculate K values. 
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where, y was the intensity of signal, x was the retention time, and T was a 
switching function, and I1 was a modified Bessel function. The fitted NLC 
parameters (a0, a1, a2 and a3) were collected for each chromatography profile 
and used for the calculation of the K according to the Eq. 11: 
0
3
C
a
K                                                                                                              (11) 
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where, C0 was the concentration of the solute injected multiplied by the width of 
the injection pulse (as a fraction of column dead volume). The Ka values were 
then calculated with K and Kd according to Eq. 2. 
2.2.1 Materials 
Caffeine, Chloramphenicol and Norethindrone with purity of 99.0%, Metoprolol 
tartrate salt and Ofloxacin with purity of 98.0% were purchased from Shanghai 
Suobio Bioscience & Technology Co. Ltd., China. Theophylline, Ethosuximide 
and Orphenadrine hydrochloride with purity of 98.0% were purchased from 
Tokyo Chemical Industry Co. Ltd., Shanghai. Theobromine and Penicillamine 
with purity of 99.0% was supplied by Sinopharm Chemical Reagent Co., Ltd., 
China. Propranolol hydrochloride with purity of 100% was provided by National 
Institute for Food and Drug Control, China. Cortisone with the purity of 99.0% 
was purchased from Merck Co., Inc., USA. Nortriptyline hydrochloride with 
purity of 98% was obtained from Sigma-Aldrich Co. LLC.  
The HP-β-CD bonded column (Astec CyclobondTM Chiral HPLC Column, 15 
cm×4.6 mm, 5 μm) were purchased from Sigma (St. Louis, MO). Ammonium 
acetate and acetonitrile (HPLC grade) were purchased from Sigma (USA) and 
J&K (China). Water was purified on a Milli-Q system (USA). The 
chromatographic system used consisted of a binary pump(G1311C), an 
autosampler (G1329B) and a diode-array detector (G4212B) (Agilent, Palo Alto, 
USA). The columns were maintained at 25 ºC with a temperature controller 
(G1316A) (Agilent, Palo Alto, USA). Chromatographic data were acquired using 
the workstation of Chemstation Rev.B.04.03 (Agilent, Palo Alto, USA). The 
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chromatograms were then analyzed using Peakfit 4.12 software (Jandel 
Scientific Software, San Rafael, CA).  
2.2.2 Methods 
2.2.2.1 Determination of Kd by peak profiling method using HPAC 
For the determination of Kd of fourteen drugs separately, the studies were 
performed on the Sigma HP-β-CD column (150×4.6 mm, 5 μm) at 25 ºC. Uracil 
was used as the conventional non-retained substance. In order to enable the 
elution of drugs in reasonable time period, 35% of acetonitrile was added into 
the mobile phase of NH4Ac (10 mM, pH = 6.80). All samples were prepared with 
the mobile phase. The flow rate was 0.4, 0.6, 0.8 and 1.0 mL·min-1. The peak 
profiling experiments were performed by injecting 10 μL sample, in which the 
concentration of caffeine, chloramphenicol, cortisone, ethosuximide, metoprolol 
tartrate salt, norethindrone, nortriptyline hydrochloride, ofloxacin, orphenadrine 
hydrochloride, penicillamine, propranolol hydrochloride, theobromine, 
theophylline, and uracil was shown in Table 4. The concentrations of sample 
were adjusted according to the response difference to confirm the linear elution 
under the above mentioned methods. All experiments were performed in 
triplicate under each set of test conditions.  
The retention time (i.e., first statistical moment) and variance (second statistical 
moment) of each chromatographic peak were obtained by using Peakfit 4.12 
software with an exponentially modified Gaussian (EMG) fit and the linear 
progressive baseline plus residual options of this program. Then the data were 
analyzed according to the published method [142-145]. 
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2.2.2.2 Determination of K by peak fitting method with HPAC  
For the determination of K by the peak fitting method, sample of 10 μL was 
injected and the UV detector was applied to measure K with the flow rate of 1.0 
mL•min-1, the elution condition of drugs was same as the method mentioned 
before (see section 2.2.2.1) for the determination of Kd. And the concentration 
of drugs was also listed in Table 4. Low drug concentration benefits Kd 
determination since linear elution should be carried out and high drug 
concentration benefits K determination because all ligands could be occupied. 
The a3 (distortion parameter) of each chromatographic peak could be obtained 
by using Peakfit 4.12 software with nonlinear chromatography (NLC) fit and the 
linear progressive baseline plus residual options of this program. Then the data 
were analyzed according to the published method [137]. 
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Table 4 The injected concentration of drugs for determination of K and Kd 
Drugs 
Drug concentration used for 
Kd determination (μg/mL) 
Drug concentration used for K 
determination(mg/mL) 
Theophylline 0.96 0.96 
Theobromine 0.91 0.18 
Paracetamol 1.00 1.00 
Caffeine 1.09 1.09 
Metoprolol  10.86 5.06 
Norethindrone 5.70 5.03 
Nortriptyline  5.24 5.05 
Ethosuximide 47.60 5.38 
Orphenadrine  48.80 5.30 
Cortisone 1.00 2.01 
Chloramphenicol 0.97 1.53 
Ofloxacin 9.05 0.36 
Penicillamine 105.60 5.63 
Propranolol  1.04 5.61 
Uracil 1.034 - 
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2.2.2.3 Modeling of drug/CD kinetic parameters with bitter taste as determined 
using the electronic tongue 
The electronic tongue test was as described in section 2.1.2.2. 
Based on the experimentally determined Ka and Kd for each drug shown in 
Table 4, 12 derivative parameters (Ka, Kd, Ka
2, Ka
3, KaKd, Ka
2Kd, KaKd
2, Ka
3Kd, 
KaKd
3, Kd
2, Kd
3, Ka/Kd) were calculated as independent variables. Before 
undertaking the modeling process, these parameters were normalized (divided 
by maximum value) in consideration of the difference of dimension and units 
between Ka and Kd. Euclidean distance between drug and corresponding drug-
HP-β-CD inclusion were used as dependent variables for modeling. 
In addition, data from the 10 bitter tasting model compounds were used to 
construct a statistical model of kinetic parameters versus taste-masking using 
SPSS statistics software (version 19.0). Independent variable reduction and 
model construction were carried out by stepwise linear optimization of the 
regression line fit as determined by R2 and P values. 
2.2.2.4 Cross-validation 
In order to find out if the model was sensitive to the presented data sets or they 
could properly predict using other data sets, 10-fold cross validation technique 
was applied.  
For the model in this research, this procedure continued ten times, and at each 
time one of the samples was considered as the test set. The cross-validation 
result was evaluated by correlation coefficient, which was calculated by Eq.4 
(see section 2.1.3.3). 
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2.2.3 Results and discussion 
2.2.3.1 The determination of Kd and K by peak profiling and peak fitting method 
As described previously [137-139], the plate height values of test drugs (HR) 
and uracil (HM,C) on the HP-β-CD column at flow rates of 0.4, 0.6, 0.8 and 1.0 
mL•min-1 were calculated (as shown in Figure 7). The linear trend between HR 
and u in Figure 7 indicated the main contribution of stationary mass transfer on 
the peak broadening of orphenadrine hydrochloride, nortriptyline hydrochloride, 
norethindrone and ethosuximide (R≥0.9885). However, the contribution of the 
B-term on the peak broadening of uracil was found to be more important than 
that of drugs. This finding was reinforced by the observations that the B-term of 
uracil was larger than that of drugs. As stated previously, this observation is 
thought to be due to the extensive and weak non-specific interactions of CD 
with the small molecules and the significant diffusion of uracil. 
 
Figure 7 Typical peak profiling results for four test drugs and uracil on HP-β-CD 
column by single compound analysis (a: orphenadrine, b: nortriptyline 
hydrochloride, c: norethindrone, d: ethosuximide) (■: plate heights for uracil 
(HM,C), ▲: plate heights for drugs (HR), △: plate heights for theoretical non-
retained substance (HM,T)) 
As expected, the stationary phase mass transfer (C-term) for uracil was also the 
dominant parameter in the Van Deemter equations, confirming the binding 
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kinetic broadening. Similar with findings described previously, it was also 
suggested that HM,T with no C-term contribution, could not be equivalent with 
the C-term dominated HM,C. Thus, it was necessary to perform a correction to 
obtain the real plate height for the theoretically non-retained substance. 
Unlike the interaction of drugs with HSA, the cavity of CDs can include a wide 
variety of ions and molecules, even the so-called non-retained void volume 
indicators, such as sodium nitrate, citric acid and uracil. In addition, the 
interaction of solutes with CDs is usually weak (Ka<10
5 M-1). The contributions 
of the C-term to the total plate height for the drug-CD combination were 
consistently found to be smaller than that for drug-HSA system. As a result, the 
differences of the longitudinal diffusion and stagnant mobile phase mass 
transfer between the retained drug and the conventional non-retained 
substances should not be neglected. Thus, plate heights for the theoretically 
non-retained substance were corrected and then the Kd values could be 
calculated. 
The data for test drugs on the HP-β-CD column were analyzed using the 
multiple flow rates peak profiling method based on the above mentioned theory, 
with the correction of the plate height for the theoretical non-retained substance. 
When plots of (HR-HM) versus (uk)/(1+k)
2 were processed, linear fits were 
observed for the fourteen drugs, the slopes of these plots were then used to 
estimate the Kd under the above mentioned conditions. The data for 
orphenadrine, nortriptyline, norethindrone and ethosuximide on HP-β-CD 
column were also analyzed with the multiple flow rates peak profiling method. 
When plots of (HR-HM) versus (uk)/(1+k)
2 were processed, linear fits were 
observed for the four drugs, with corresponding correlation coefficients of 0.989, 
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0.979, 0.949, 0.966 and intercepts of 0.0010, 0.0011, 0.0006, 0.0002 for 
orphenadrine, nortriptyline, norethindrone and ethosuximide (as shown in 
Figure 8). The intercepts were all close to zero, indicating the main contribution 
of C-term on the peak broadening of the four drugs. The responses were 
consistent with the linear behaviour that was predicted for (HR-HM) versus 
(uk)/(1+k)2 in Eq. 4. The slopes of these plots were then used to estimate the Kd. 
The Kd were estimated for orphenadrine 12.56±0.09 s
-1, nortriptyline 14.01±1.74 
s-1, norethindrone 23.61±0.14 s-1 and ethosuximide 9.71±0.27 s-1 respectively 
over the flow rate range of 0.4-1.0 mL·min-1. As for the K values of the thirteen 
drugs, which could be obtained according to the Eq. 11 by peak fitting method 
(see section 2.2), the Kd and K values determined were as listed in Table 5. 
 
Figure 8 Plots of (HR-HM) versus (uk)/(1+k)
2 of four drugs on HP-β-CD column 
by single compound analysis (a, orphenadrine hydrochloride: y = 0.16x + 
0.0019, R2 = 0.979; b, nortriptyline hydrochloride: y = 0.16x + 0.0010, R2 = 
0.978; c, norethindrone: y = 0.09x + 0.0004, R2 = 0.968; d, ethosuximide: y = 
0.20x + 0.0002, R2 = 0.978) 
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Table 5 Kd and K values determined by the peak fitting method  
Drugs K(±SD)(M-1) Kd (±SD)(s
-1) 
Theophylline 0.01±0.00 5.26±0.20 
Theobromine 0.92±0.00 1.21±0.07 
Caffeine 12.00±0.14 1.81±0.68 
Metoprolol  40.36±0.34 11.03±0.96 
Norethindrone 4.40±0.00 23.61±0.14 
Nortriptyline  102.94±12.02 14.01±1.74 
Ethosuximide 0.69±0.13 9.71±0.27 
Orphenadrine  24.65±0.05 12.56±0.09 
Cortisone 5.25±0.04 22.16±1.40 
Chloramphenicol 0.41±0.00 11.02±2.55 
Ofloxacin 2005.79±1.70 0.12±0.01 
Penicillamine 0.29±0.01 1.07±0.06 
Propranolol  108.06±0.49 26.11±8.77 
See section 2.2.2.2 for detail of methodology used 
2.2.3.2 Taste evaluation of test compounds using the electronic tongue 
The results of electronic tongue are shown in 2.1.3.1. 
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2.2.3.3 Modeling 
By stepwise regression for independent variable reduction, seven parameters 
with notable influence on the taste masking effect including Ka
3, Kd, Ka
2Kd, Ka
3Kd, 
KaKd
3, Kd
2 and Ka/Kd were identified from twelve pre-set kinetic parameters. 
Based on the six selected parameters, a multiple-linear regression model was 
established, as given in Eq. 12 with R2=0.98 and P≤0.05.   
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     (12) 
It is conventionally believed that Ka and Kd for drug/macromolecule 
complexation should have a positive and negative correlation with taste 
masking respectively. However, both of Ka
3, Kd
2 and Ka
2Kd possessed negative 
correlation with Euclidian distance, while other parameters had positive 
correlation with taste masking effects. A three dimensional model for distance 
as a function of Ka and Kd was depicted (Figure 9). 
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Figure 9 Three dimensional model based on thirteen model bitter drugs data 
(blue balls) for relationship of Ka, Kd measured by HPAC and taste masking 
effects (as measured by the electronic tongue) of drug/ HP-β-CD complexation  
From this model, it could be observed that the distance rapidly increased when 
Kd was closed to zero, which implied very strong drug-CD inclusion. Therefore, 
the concentration of free bitter drug molecules in the solution was too low to be 
perceived. Additionally, in the white area of Ka < 100 and Kd > 25, the distance 
decreased to zero, which demonstrated that drugs in this area could poorly form 
drug-HP-β-CD inclusion to mask bitter taste. However, distance has been rising 
as Ka value increased from 0 to 600. Meanwhile, a rise following by a fall of 
distance could be observed as the Kd value from 0 to 20.  
The model produced a good correlation between taste masking and kinetic 
parameters of drug-HP-β-CD complexation, although the number of test 
samples was limited. Compared with SPRi method, it is difficult for HPAC to 
determine kinetic parameters in high-throughput.  
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2.2.3.4 Cross-validation and prediction 
The correlation of determined distance (Y) as a function of predicted distance (X) 
of each drug was calculated by 10-fold cross-validation (Figure 10). It is well 
known that two sets of data strongly correlate with each other when the 
correlation coefficient is about 0.8 to 1. A good correlation was obtained as 
given in Eq. 13 with correlation coefficient of 0.82, P<0.05 (bivariate correlated 
analyse by SPSS). 
06.706054.0  XY                                                                                 (13) 
 
Figure 10 The correlation-ship of predicted distance versus determined distance 
for constructed model by 10-fold cross-validation  
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2.3 Comparison of Kinetic Parameters Obtained by 
SPRi and HPAC on Taste masking Models 
From the three dimensional models established by SPRi and HPAC methods, it 
could be observed that the general tendencies of the two models was almost 
the same (Figure 11). The distance rapidly increases when Kd is closed to zero, 
because K (Ka/Kd) exerts a positive influence for both models and Kd is the 
denominator in this relationship. Also, in the white area (see Figure 11) Ka is a 
small value and Kd is in big value, the distance decreases to zero. This 
demonstrates that drugs in this region are poorly complexed by HP-β-CD and 
hence the drug-HP-β-CD inclusion complex is likely to rapidly dissociate to 
release free drug.  
 
Figure 11 Comparison of two models relating Ka and Kd for drug-CD reversible 
complexation measured by SPRi or HPAC and taste masking measured using 
the electronic tongue  
However, the SPRi model data, e-tongue Euclidean distance rises to a crest 
followed by a gradual reduction as CD/drug Ka and Kd values increase. By 
Model based on SPRi Model based on HPAC 
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comparison, the HPAC model showed that e-tongue Euclidean distance 
increases linearly with CD/drug Ka and Kd. This difference might be caused by 
the distribution of Ka values obtained by two methods. Ka values of most of 
drugs based on HPAC measurement are very similar, all exhibiting small values 
(less than 110 M-1 except ofloxacin is about 2005 M-1). In contrast the 
distribution of Ka value based on SPRi is more uniform (within three orders of 
magnitude). Although the correlation coefficients for both models was>0.8, the 
larger coefficient of SPRi method and smaller intercept indicate that the 
systematic error for the model based on SPRi is smaller than that based on 
HPAC. Additionally, compared with SPRi based model an obvious area with 
distance of zero could be seen in HPAC based model even Kd is small and Ka is 
with large value which might be also caused by systematic error. Firstly, in SPRi, 
drug molecules are immobilized over the sensor surface and CDs are used as 
the mobile phase, which is totally reversed in HPAC, where the drugs are used 
as a mobile phase and CDs are modified and fixed onto the surface. In other 
words, chemical groups specifically responsible for bitter taste would not 
necessarily be bound on the microarray. The microarray bound drugs would 
therefore not necessarily present the correct functionality to the HP-β-CD and 
hence influence the drug/CD kinetic parameters measured. Photo-cross-linking 
technique is used to immobilize the drug molecules which allowed one molecule 
to display in various orientations. Each orientation may have different binding 
affinity to the specific CD and therefore, the kinetic constant we have obtained 
from SPRi is probably the average of different multiple orientations. Non-
specific binding which is present in all systems might also contribute to the 
kinetic parameters determined. The taste-masking effect would be influenced by 
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various factors besides inclusion formation. These include competitive binding 
of chemical groups responsible for bitter (internal or external binding to CD 
cavity) as well as the natural sweet intensity of CD. These properties will be 
revealed by Euclidean distance determination using the Electronic Tongue. In 
summary, besides drug concentrations present in free and complexed forms, 
non-specific bindings and other interactions in the SPRi determination should 
be taken into account. 
A further issue concerning the measured drug Ka values using by HPAC and 
SPRi is that the calculated value may be influenced by the mobile phases 
employed. Using HPAC, for solubility purposes acetonitrile is the required 
solvent for drug dissolution, which, per se, has a competitive interaction with 
HP-β-CD. Acetonitrile will reduce the polarity and enhance elution capability of 
the mobile phase. As a result, the inclusion of drugs into the cavity of HP-β-CD 
could be hindered and lead to a reduction in measured Ka. In contrast, for SPRi, 
drugs were immobilized on the microarray and HP-β-CD dissolved in PBS 
added, which is at a similar pH and ionic strength similar to that found in the 
mouth cavity environment. And the drug concentrations varied a lot in HPAC 
which might lead to greater systematic error than SPRi. Additionally, the flow 
rates of the two methods are also not the same with flow rate for SPRi being 
much less than that for HPAC.  A lower flow rate will facilitate the association 
process of drug/HP-β-CD allowing greater ease of discrimination between the 
interaction of these guest and host molecules.  
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2.4 Formulation Optimization based on Kinetic 
Parameters of Drug-CD Inclusion 
Paracetamol, a bitter tasting medication used to treat many conditions such as 
headache, muscle aches, arthritis, backache, toothaches, colds and fevers, was 
used as a model drug. A number of taste masking methods were tried, including 
granulation and microencapsulation based on solvent evaporation. Dissolution 
testing showed granulation and microencapsulation released more than 60% of 
the paracetamol within 30 seconds. A further formulation of paracetamol lipid 
microspheres prepared by spray congealing released less than 6% paracetamol 
within 30 seconds. However, a slightly bitter taste could still be perceived due to 
the 6% of released drug. Paracetamol lipid microspheres in association with β-
CD inclusion were prepared for taste masking. By spraying a fusion mixture of 
paracetamol, octadecanol and Eudragit into cold air to obtain solid 
microspheres and sieving, the size distribution and sphericity of microsphere 
were acceptable (close to 1) as characterized by inverted microscope 
examination and flowability testing. The dissolution test indicated that the 
release of paracetamol from lipid microspheres followed zero-order kinetics. 
Whilst only a small amount (less than 6%) of paracetamol was released from 
the microspheres within 30 seconds, the bitter taste could still be perceived. 
Therefore, in order to prevent the released paracetamol impacting on the bitter 
taste receptors, β-CD was added to complex any paracetamol that was 
released. However, it was important to minimise the amount of β-CD added to 
minimise the interference of β-CD on subsequent paractemol formulations. By 
calculation, the theoretically amount of β-CD required was obtained. The 
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electronic tongue test was carried out to evaluate taste masking because 
concentration-dependent methods such as HPLC, could not distinguish free 
paracetamol from paracetamol in complexation with β-CD. 
Paracetamol lipid microsphere with β-CD follows a kinetic model in aqueous 
solutions including saliva (Figure 12). 
 
Figure 12 The schematic diagram showing paracetamol distribution behaviour 
in aqueous media including saliva 
The drug in microsphere (X1) follows first-order kinetics [146]: 
kteDX 1                                                                                                  (14) 
where, D is initial drug dosage in the microsphere and k is the release rate 
constant. 
Free drug in saliva (X2) is the drug released subtracted from that in β-CD 
inclusion (X3): 
  3-2 1 XeDX kt                                                                                (15) 
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Assuming β-CD and drug can reach an equilibrium state rapidly, X3 is mainly 
determined by the β-CD concentration (Y) and the equilibrium constant between 
β-CD and drug (K) and X2: 
YKXX 23                                                                                                     (16) 
Meanwhile, in consideration of drug-CD inclusion formed as 1:1 in molar ratio, Y 
is decreasing with formation of X3: 
30 XYY                                                                                                     (17) 
where Y0 is the initial β-CD concentration. 
X1, X2, X3 and Y could be obtained by Mathematica software: 
kteDX 1                                                                                                   (14) 
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When t , following equations could be obtained: 
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D = 0.026462027 M and K = 142.3 M-1 [137] when dosage is 20 mg (strength) 
and saliva volume is 5 mL. 
2lim X
t 
 (equilibrium concentration of free 
paracetamol)  gradually decreases with increase of Y0 ( concentration of β-CD). 
 
Figure 13 Effects of Y0 (the concentration of β-CD) as a function of 2lim X
t 
 (the 
equilibrium concentration of free paracetamol) 
It is rationalised that a combination of lipid microspheres and β-CD could be 
used to retard drug release (k) including drug released into saliva.  The result of 
which is a better taste-masking effect i.e. the co-operation of microsphere and 
β-CD will work in concert to prevent the contact between bitter paracetamol and 
taste buds. 
Since people normally complete the swallowing process within 30 s, it can be 
estimated that within this time the free concentration of paracetamol should be 
less than 35 μg/mL since this is the threshold concentration for people to 
perceive bitter taste of paracetamol [147]. When drug loaded lipid microspheres 
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equivalent to 20 mg paracetamol is administered, the free paracetamol 
concentration is 80 μg/mL at 30 s (in 5 mL saliva). By theoretical calculation, 
K=142.3 M-1, k=0.001270 s-1, D=0.026462027 M at 30 s, from Eq. 18: 
2
2 0 00.00338235 ( (147.826 0.8926) 0.607658 147.826 0.8926)X Y Y                (24) 
When X2≤0.0002315 M (35 μg/mL), Y0≥0.02375 M. Therefore, as the dosage 
of β-CD is 134.8 mg (6.74:1 with drug in mass ratio), concentration of free drug 
released could be reduced to 35 μg/mL by inclusion of β-CD. 
2.4.1 Materials 
Paracetamol (Anhui Fengyuanlikang Pharmaceutical Co. Ltd.); Octadecanol 
(Hunan Erkang Pharmaceutical Co. Ltd.); Eudragit E100 was selected because 
it dissolved in aqueous media with pH<5 (pH of saliva between 6.8 and 7.4) 
(Shanghai Chineway Pharmaceutical Tech. Co. Ltd.); β-CD (Anhui Shanhe 
Pharmaceutical Co. Ltd.); Sodium phosphate monobasic dehydrate, Sodium 
hydrogen phosphate, Phosphoric acid (Sinopharm Chemical Reagent Co., Ltd., 
China.) Electronic contact thermometer (ETS-D5, IKA, German); Inverted phase 
contrast microscope (TS-100F, Nikon, Japan); Ultra performance liquid 
chromatography (UPLC) (1290, Agilent, America); Particle sizing systems 
(Camsizer XP, Retsch, German); α-Astree electronic tongue Ⅱ (Alpha MOS, 
Toulouse, France); Dissolution apparatus (ZRS-8G, Tianjin Haiyida Co., Ltd, 
China); Spray gun (W-71, Iwata, Japan); Electrothermal draught drying cabinet 
(BPG-9140A, Shanghai Yiheng Instruments Co., Ltd, China); Vapour-bathing 
constant temperature vibrator (Taicang Experimental Equipment Factory, 
China); Electronic scales (ML203, Mettler Toledo, Switzerland); Electronic 
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scales (TE601-L, Sartorius, Geman); pH meter (PP-20-P11, Sartorius, Geman); 
Water purification system (Milli-Q, Millipore Corporation, America) 
2.4.2 Methods 
2.4.2.1 Preparation of paracetamol lipid microspheres 
Paracetamol lipid microspheres were prepared by the addition of an appropriate 
amount of Eudragit E100, which can only dissolve at pH≤5, into octadecanol at 
100oC (Paracetamol:Octadecanol:Eudragit E100 = 30:60:10  w/w). Paracetamol 
as a micronized powder was gradually added whilst stirring the system at 1000 
rpm and 100oC to produce a uniform mixture. The mixture was then 
immediately poured into the reservoir of a spray gun preheated to 90oC in a 
drying oven and sprayed such that the air dried microspheres at room 
temperature (approx 25oC) were collected from stainless steel trays. Batch 
sizes were between 30-50 g. The solid microspheres were sieved and the 
fraction size 160-200 mesh (~75-96 μm) was collected for further study as 
described previously [147]. 
2.4.2.2 Morphology characterisation of paracetamol lipid microspheres 
The morphology of paracetamol lipid microspheres sieved between 160-200 
mesh were investigated by inverted phase contrast microscopy.  
Examinations of the size distribution, sphericity and symmetry were studied 
using the Camsizer XT particle sizing systems. In this study, about 100mg of 
paracetamol lipid microspheres were transported from a hopper to the analyzing 
area, and then injected by compressed air, which was set at 30 Kpa. The 
shadows projections of the microspheres were captured by cameras, following 
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by transforming greyscale images through a multistep algorithm into binary 
images to determine the exact outlines. All particle size and particle shape 
parameters, including sphericity and symmetry, could be measured on this 
basis.  
2.4.2.3 1HNMR characterisation of paracetamol lipid microspheres 
Paracetamol, β-CD and a physical mixture of paracetamol with β-CD in an 
optimized ratio (1:6.74 w/w) were vibrated for 5 min in water (10 mL) at 37 oC 
and mixing speed of 50 rpm. Samples (10 mL) were taken, filtered and freeze-
drying. The freeze-drying powders were re-dissolved in D2O and then 
determined by 1HNMR. 
2.4.2.4 Dissolution test on paracetamol lipid microspheres 
For the in vitro dissolution test to mimic dissolution in saliva, microspheres 
containing 20mg of paracetamol (pharmaceutical grade material) particle size 
fraction 160-200 mesh were assessed in triplicate for each batch of the 
microspheres prepared using the paddle method according to the Chinese 
Pharmacopoeia 2010 with a rotation speed of 50 rpm. Distilled water (200 mL) 
was used as the dissolution medium at 37 ± 0.5 oC. Aliquots of 2mL solution 
samples were withdrawn at 10, 30, 60, 90, 120, 180, 240, 300 s and an equal 
volume of distilled water added to each sample solution immediately after 
collection. This solution was immediately filtered through a 0.22 μm membrane 
and analysed by an Agilent 1260 series HPLC system (Agilent Technologies 
Inc., China). The mobile phase consisted of methanol-phosphate buffer (pH 4.5) 
(20:80, v/v). Elution was performed at 25 oC at a flow-rate of 1 mL/min. The 
wavelength of the detector was set at 254 nm. The dissolution test could not 
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distinguish free paracetamol from that included in β-CD. Therefore it was 
difficult to evaluate the taste masking effect of β-CD using the dissolution test. 
Subsequently, the electronic tongue was used to evaluate taste masking effect 
of β-CD. 
2.4.2.5 Determination of taste masking effects by electronic tongue 
A series of paracetamol standard solutions (P1, P2, P3, P4) were prepared by 
addition of an appropriate amount (0.30, 1.00, 3.00, 10.00 mg) of paracetamol 
to 80mL of deionized water. Then paracetamol lipid microsphere (M), 
paracetamol lipid microsphere in association with β-CD at an optimized mass 
ratio of 1:6.74 (C), and paracetamol-β-CD inclusion at mass ratio of 1: 6.74 (B) 
equal to 10 mg of paracetamol were transferred into dissolution cups with 100 
mL deionized water at paddle speed of 50 rpm. The samples were withdrawn at 
30 s and filtered. The assays were determined on an Astree electronic tongue 
system equipped with an Alpha M.O.S. sensor set #2 (for pharmaceutical 
analysis) composed of 7 set of sensors (ZZ, AB, BA, BB, CA, DA, JE) on a 13-
positions autosampler (using 80 mL-beakers). Acquisition times were fixed at 
120 s. The data generated on the Astree system was processed using 
multidimensional statistics on AlphaSoft V12.3 software. Samples 
measurements were replicated at least eight times and the values of the last 
three measurements were used in the data analysis. Average values at 120 s 
were used to build the taste maps. Astree sensors were washed by deionized 
water between each sample measurement.  
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2.4.3 Result and discussion 
2.4.3.1 Morphology characterization of paracetamol lipid microspheres 
Size distribution analysis indicated that the mean diameter of the microspheres 
was 97.6 μm (Figure 14). The morphology of paracetamol lipid microsphere 
showed particles with good sphericity (i.e., sphericity (SPHT) of 0.949 and 
symmetry factor of 0.953, which were both close to 1) [148]. Generally, particles 
with regular shape and smooth surface have smaller surface area as well as 
slower dissolution rate than the rough particles, which is likely to influence the 
taste masking performance.  
     
Figure 14 Morphology of microspheres. 2D micrograph, morphology features 
(left), and the size distribution (right) of paracetamol lipid microspheres 
2.4.3.2 1HNMR characterization of paracetamol lipid microspheres 
As could be seen in the 1H NMR spectra, there were two characteristic peaks 
for paracetamol: the H-2, H-6 doublets at 7.12 ppm and the CH3 singlet at 2.01 
ppm. All the characteristic chemical shift values of paracetamol in the physical 
mixture increased. The spectra show that hydrogen bonds were formed 
between the oxygen on the phenolic hydroxyl group, the nitrogen on the imino 
group of paracetamol and the hydrogens on the hydroxyl groups in β-CD. 
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Therefore, it was likely that β-CD could include paracetamol in a short time in 
solution state. 
 
Figure 15 1H NMR spectra (left: the H-2, H-6 doublets of paracetamol; middle: 
the CH3 singlet of paracetamol; right: multiple peaks of β-CD in 3.4 ppm-4.2 
ppm) of β-CD, paracetamol (P), the physical mixture of βCD and paracetamol 
(B) 
2.4.3.3 Dissolution test 
The short term dissolution test (within 120s) was used to establish the release 
of free paracetamol from the formulations which would subsequently contribute 
the bitter taste experience (Figure 16). The release behaviour of paracetamol 
particle sized by the 160-200 mesh was tested. It was observed that 
paracetamol released rapidly under the sink conditions used, with 70% at 30 s 
and 100% within 120 s. In contrast, the paracetamol lipid microspheres 
exhibited sustained-release characteristics. When Eudragit E100 was added to 
the formulation, the release rate of paracetamol fell dramatically. Less than 2% 
paracetamol released at 30 s and approximately 35% at 300 s. 
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Figure 16 Drug release profile of paracetamol and paracetamol lipid 
microspheres prepared using octadecanol and Eudragit E100 
2.4.3.4 In vitro taste masking evaluation (Astree electronic tongue) 
The samples collected from the dissolution test at 30 s from paracetamol, 
paracetamol/β-CD complexes, lipid microspheres and lipid microspheres 
combined with β-CD were evaluated for taste masking using the electronic 
tongue. The taste maps were generated and analysed by PCA software.  
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Figure 17 Electronic tongue „„taste map‟‟: Global signal comparison (PCA 
analysis of the electrode responses) from paracetamol (P), paracetamol / β-CD 
inclusion complex (B); lipid microspheres (M); lipid microspheres combined with 
β-CD (C) 
From the taste map of electronic tongue, it was clear that the taste of the 
paracetamol standard solutions (P1, P2, P3, P4), paracetamol included by β-CD 
(B) or lipid microspheres (M) were different. For paracetamol API standard 
solutions, triangles shifted from right to left as reduction of concentrations, 
indicating that samples with less bitterness should be on the left of taste map. 
Therefore, a noticeable taste masking effect was observed for paracetamol 
mixed with β-CD compared with paracetamol API standard solutions. A better 
taste masking effect was produced by lipid microspheres on the left of the taste 
map with larger distance to paracetamol API standard solutions than 
paracetamol mixed with β-CD. Lipid microspheres combined with β-CD showed 
an optimal taste masking effect for paracetamol although the lipid microspheres 
per se played a leading role in the total taste masking observed. The results for 
taste masking as evaluated by the electronic tongue were in accordance with 
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the kinetic model established previously established (see section 2.4), namely, 
the order of bitter intensity was paracetamol > paracetamol / β-CD inclusion 
complex > paracetamol lipid microspheres > paracetamol lipid microspheres 
combined with β-CD. 
Paracetamol was used as a model bitter tasting drug to investigate the influence 
of lipid microspheres combined with β-CD inclusion as a method to mask the 
bitter taste of poorly soluble drugs. In order to optimize the formulation and 
minimise the amount of β-CD, a kinetic model was established. This could be 
used to calculate distribution of drug in medium, lipid microspheres and β-CD 
inclusion. It provided a basis to determine the optimal amounts of lipid 
microspheres and β-CD to reduce the concentration of bitter drug under the 
threshold perception concentration (35 μg/mL). Finally, the combination drug 
delivery systems were prepared and characterized by 1HNMR and electronic 
tongue. The results tested by electronic tongue indicated that the paracetamol, 
paracetamol lipid microspheres, paracetamol-β-CD inclusion and combination 
drug delivery system showed different taste characteristics, with the order of low 
to high bitter perception; combination drug delivery systems < lipid 
microspheres < paracetamol / β-CD inclusion < paracetamol. It was proved that 
taste masking of bitter drug could be achieved using a combination of lipid 
microspheres and CD inclusion. The result of 1HNMR also demonstrated that 
combination taste masking was jointly achieved through the inhibition of drug 
release by the lipid microspheres and the inclusion of the free paracetamol by 
β-CD. 
In addition to the molecular basis of bitterness prevention, the microstructures 
of the formulations could also closely relate to effectiveness in taste masking, 
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especially for taste masking solid formulations, such as particles or granules. 
However, the taste masking characteristics of drug formulations have not been 
quantitatively correlated with the drug-in-formulation internal microstructure. 
Therefore, a quantitative method to correlate the detailed structural information 
along with the drug release behaviour will provide mechanistic and new 
knowledge for taste masking technologies to guide rational design of products. 
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Chapter 3 Fine Microstructure and Chemical 
Distribution of Taste Masking Microspheres 
Based on Synchrotron Radiation  
 
The microencapsulation and microspheres are valuable techniques applicable 
to mask the unpleasant taste as well as to protect materials from volatilizing and 
oxidation [149]. Microencapsulation processes are generally based on the 
principle of solvent extraction or evaporation. However, residual organic 
solvents cause risk to safe use of pharmaceutical quality formulations. 
Therefore, other techniques such as spray drying and spray congealing are also 
utilized for microencapsulation [150]. It is well known that many properties of 
materials are determined by their particle structures. However, at the particle 
level, it seems that there is an absence of reports about the relationship 
between taste and particle microstructure. 
From another perspective, in vitro drug release testing approaches have been 
widely used to predict or quantify the effectiveness of taste masking techniques 
used. Characterisation of bitter drug release under conditions that mimic the 
oral cavity fluid composition could effectively predict the taste masking 
effectiveness of a formulation designed to reduce contact between the bitter 
active pharmaceutical ingredient (API) and oral cavity taste bud regions [151, 
152].  
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Moreover, the rate and mechanism of the drug release from solid dosage forms 
strongly depend upon morphology, such as shape and surface, of the dosage 
form. For example, „rough‟ pellets showed a faster release rate than smooth or 
spherical pellets (after 2 h of release) [153]. Toshio Yajima et al prepared wax 
matrix of clarithromycin by different conditions. It was found that the morphology 
properties which were influenced by atomizer wheel speed affected the release 
behaviour of the matrix to control the taste properties [154].  
The internal microstructure of pharmaceutical tablets not only influences the 
mechanical strength of the tablets but also impacts the release rate of APIs 
[155]. A good correlation has been also reported between the total porosity, 
mean pore diameter and drug release rate for erosion matrix drug loaded 
pellets, while these porosity parameters were important when evaluating the in 
vitro performance during the controlled release of an insoluble drug [156]. 
Recently, SR-μCT has been used for the microstructural investigation of pellets, 
and showed that the release profile of a single pellet correlated significantly with 
steric features such as drug loading, volume, and surface area [157]. These 
results suggest that the microstructure of particles or granules used to taste 
mask are closely relates to their effectiveness in this process. Moreover, 
characterization and evaluation of taste masked products are of significant 
interest. In addition to drug release testing, conventional methods have been 
employed for powders, including particle size analysis, porosity measurement, 
morphology analysis, differential scanning calorimetry (DSC) and x-ray 
diffraction (XRD) [158-164]. However, these methods are not able to directly 
investigate the internal fine structures and identify the roles in taste masking of 
the formulation ingredients. Therefore, a quantitative method to correlate the 
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detailed structural information with the drug release behaviour will provide 
mechanistic and new knowledge for taste masking technologies. 
SR-μCT, a novel technique for investigation of the internal three dimensional 
(3D) structures of objects, shows great possibilities for quantitative evaluation 
and design for solid drug delivery systems. Our previous studies have shown 
that the interior porous channels and irregular structures can be quantified by 
the fractal dimensions, which were also well correlated with the drug release 
kinetics of felodipine osmotic pump tablets [165]. After the surface morphology 
and the internal 3D structure of felodipine osmotic pump tablets was visualized, 
the intrinsic drug release kinetics and 3D parameters, such as surface areas of 
the remaining core, were quantitatively elucidated using SR-μCT [166]. SR-μCT 
has also been used non-destructively to investigate the mixing and segregation 
of granular materials in three-dimensions combined with statistical methods 
[167]. Additionally, Shuji Noguchia applied CT using synchrotron X-ray radiation 
for the structural analysis of fine granules containing drugs prepared by melt 
granulation with irregular shape [168]. 
In this study, paracetamol was used as a model for bitter tasting drugs. 
Paracetamol lipid microspheres prepared by spray congealing were examined 
by SR-μCT to give quantitative analysis for the internal 3D structure and taste 
masking. The primary objectives were to study the micro-structural basis of lipid 
microspheres for taste masking by sustaining the release of drug and further to 
provide new knowledge and method for evaluation of taste masking 
formulations.  
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3.1 Fine Microstructure of Taste Masking Lipid 
Microsphere Based on SR-μCT 
3.1.1 Materials 
Paracetamol with purity of 99.45% was provided by Anhui Fengyuanlikang 
Pharmaceutical Co. Ltd., China. Octadecanol and Eudragit E100, as the 
excipients for taste masking were supplied by Hunan Erkang Pharmaceutical 
Co. Ltd. and Hanghai Chineway Pharmaceutical Tech. Co. Ltd., respectively. 
Sodium phosphate monobasic dehydrate, sodium hydrogen phosphate and 
phosphoric acid, used for dissolution test, were provided from Sinopharm 
Chemical Reagent Co., Ltd., China. 
Taste masking microspheres were prepared using a spraying technique (Spray 
gun, W-71, Iwata, Japan). Inverted phase contrast microscopy (TS-100F, Nikon, 
Japan) and a particle sizing system (Camsizer XT, Retsch, Germany) were 
used for morphology characterization. Dissolution test was performed using a 
dissolution apparatus (ZRS-8G, Tianjin Haiyida Co., Ltd., China). The 
Synchrotron radiation X-ray microtomography scans were carried out at the 
Shanghai Synchrotron Radiation Facility (SSRF) in Shanghai Institute of 
Applied Physics, Chinese Academy of Sciences (Shanghai, China). Data were 
analyzed using the commercially available software VGStudio Max (Version 2.1, 
Volume Graphics GmbH, Germany) and Image Pro analyzer 3D (version 7.0, 
Media Cybernetics, Inc., Bethesda, MD, USA). 
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3.1.2 Methods 
3.1.2.1 Preparation of paracetamol lipid microspheres 
The preparation process was described in section 2.4.2.1.  
The various formulations are shown in Table 6. The solid microspheres were 
sieved and the fraction sizes between 160-200 mesh (~75-96 μm) and 80-100 
mesh (~150-180 μm) were collected for further study.  
Table 6 Formulation of Microspheres 
Ingredients 
Formulation Codes and Compositions (%w/w) 
F1 F2 F3 F4 F5 
Paracetamol 33.3 32.3 31.7 30.8 30 
Octadecanol 66.7 64.5 63.3 61.7 60 
Eudragit E100 - 3.2 5.0 7.5 10 
 
3.1.2.2 Morphology characterization of paracetamol lipid microsphere 
The process of morphology characterization of paracetamol lipid microsphere 
was described in section 2.4.2.2. 
The flowability of the microspheres was evaluated by pouring powder of 
microspheres onto a horizontal surface to form a conical heap. The angle of 
repose between the surface of the pile and the horizontal surface was 
measured. 
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3.1.2.3 Short term in vitro dissolution test 
The process of short term in vitro dissolution test for paracetamol and 
paracetamol lipid microspheres (F1-F5) was described in section 2.4.2.4. 
3.1.2.4 X-ray powder diffraction  
Dissolution samples at 0, 5, 60 mins of microspheres with 10% Eudragit E100 
(F5) and without Eudragit E100 (F1) were investigated by X-ray powder 
diffraction (XRD). The XRD patterns were measured on a Bruker D8-ADVANCE 
X-ray diffractometer using Cu–Kα radiation (λ = 1.5418 Å). The voltage and 
current were 40 kV and 40 mA, respectively. Reflection mode was used in the 
2θ range of 3-40° with a scan speed of 15° min−1 (step size 0.025°, step time 
0.1 s) by a LynxEye detector. All the data were acquired at ambient temperature 
(20 oC). The data were imaged and integrated with RINT Rapid and peak-
analyzed with Jade 6.0 software from Rigaku. Calibration of the instrument was 
performed using a Corindon (Bruker AXS Korundprobe) standard. 
3.1.2.5 SR-μCT 
Microspheres were packed and set in polypropylene pipette tips with one end 
sealed and then measured by SR-μCT. For the structural investigation, 
microspheres containing 10% w/w Eudragit E100 and without Eudragit E100 
were selected to determine the effect of Eudragit E100 on structural features 
and correlated with drug release. In consideration of the resolution of the X-ray 
image detector used in CT scans, paracetamol crystals and microspheres 
sieved between 80-100 mesh were selected for investigation.  Drug dissolution 
test was also carried for this size fraction of microspheres. SR-μCT images 
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were acquired with beam line BL13W1 at Shanghai Synchrotron Radiation 
Facility (SSRF). In order to investigate the distribution of low Z materials 
(paracetamol and octadecanol) in the microsphere, the propagation-based 
imaging (PBI) method was used for the phase contrast imaging for the simplest 
experimental implementation. According to the preliminary experiments and 
also literature references, the imaging parameters were optimized [157, 169, 
170]. The theoretical complex refractive index indicated that in order to enhance 
the phase contrast between paracetamol and octadecanol, the X-ray with a 
lower energy should be selected for the imaging. For the consideration of 
properties including composition, density and fractions, samples were scanned 
at 13.0 KeV for the higher flux to reduce the imaging times (according to the 
spectral flux profile of BL13W, the highest flux could be obtained near 13 KeV). 
In order to enhance the contrast to show the slight difference in density between 
paracetamol and octadecanol, the sample-to-detector distance was set at 12 
cm after a series of confirmatory studies. After penetration through the sample, 
the X-rays were converted into visible light by a Lu2SiO5: Ce scintillator (10 μm 
thickness). Projections were magnified by diffraction-limited microscope optics 
(10×magnification) and digitized by a high-resolution 2048 pixel × 2048 pixel 
sCMOS camera (ORCA Flash 4.0 Scientific CMOS, Hamamatsu K.K, Shizuoka 
Pref., Japan). The pixel size was 0.65 μm and the exposure time was 1 s. For 
each acquisition, 900 projection images were captured. Flat-field and dark-field 
images were also collected during each acquisition procedure, in order to 
correct the electronic noise and variations in the X-ray source brightness. 
The projected images for the samples at each time intervals (0, 5, 60 min) of 
drug dissolution test were reconstructed using the X-TRACT SSRF CWSx64 
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(CSIRO, Commonwealth Scientific and Industrial Research Organization, 
Australia, http://www.ts-imaging.net) to perform a direct filtered back projection 
algorithm. To enhance the quality of reconstructed slices, propagation-based 
phase contrast extraction was carried out. For the principle of phase contrast 
imaging, the amplitude and phase of X-ray were affected by the interaction of 
the wave with matter and the forward diffraction could formally be described by 
the complex refractive index (n) of the medium as 
n = 1 − δ + iβ                                                                                                     (25) 
The refractive index decrement δ results in a phase shift, and the absorption 
index β is linked to the linear absorption coefficient μ. The theoretical values of 
β and δ were calculated with the X-ray attenuation properties model of DCM 
(software for the data-constrained modeling and characterization of material 
compositional microstructure and properties, which was developed by CSIRO, 
http://research.csiro.au/dcm). At the beam energy of 13 KeV, the theoretical δ of 
octadecanol and paracetamol were 1.14e-6 and 1.68e-6, the corresponding β 
values were 6.75e-10 and 1.44e-9. As described in the paper [171], the larger 
sample-to-detector distances increased the contrast primarily due to the 
contribution from differences in the refractive properties across the sample in 
addition to the differential absorption. In combination with homogeneous 
Transport of Intensity equation (TIE-Hom) phase retrieval can achieve high 
quality reconstructed 3D images. But the value of β can be accurately 
reconstructed with TIE-Hom and conventional CT reconstruction from a single 
projection image per view angle. In contrast, the accuracy of reconstruction of δ 
depends strongly on the choice of the “regularization” (δ/β) parameter in TIE-
Hom. During phase extraction, the parameter of δ/β was adjusted at 1200 
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according to the theoretical values. After phase retrieval and reconstruction, the 
calculated β of octadecanol and paracetamol were about 7.30e-10 and 1.10e-9 
respectively. Then, for all samples the range of β values between 0 to 1.70e-9 
in the images were truncated and rescaled to a grey value of 0 to 255 (8 bit grey 
level) [172]. The 3D rendered data were analyzed with commercially available 
software VGStudio Max (Version 2.1, Volume Graphics GmbH, Germany) and 
Image Pro Analyzer 3D (Version 7.0, Media Cybernetics, Inc., USA) to obtain 
qualitative and quantitative data, respectively. 
3.1.3 Result and Discussion 
3.1.3.1 Morphological characterization of paracetamol lipid microspheres 
The result of morphological characterization of paracetamol lipid microspheres 
was described in section 2.4.3.1. In addition, the flowability of the microspheres 
was also found to be good, with the angle of repose at 29°.  
3.1.3.2 Short term in vitro dissolution 
The short term dissolution test within 120 s was used to indicate the availability 
of free paracetamol as an indication of bitter taste released from the 
formulations (Figure 18). The release behaviour of paracetamol powder passed 
through 160-200 mesh was also tested. It was observed that it released rapidly 
under the sink condition, with 70% at 30 s and 100% within 120 s. In contrast, 
the paracetamol lipid microspheres (Formulations F1-F5) exhibited sustained-
release characteristics. When Eudragit E100 was added to the formulation, the 
release rate of paracetamol fell dramatically. However, as the Eudragit E100 
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concentration increased from 3.2% to 7.5% w/w in F2-F4, the release 
behaviours were similar, followed by a further decline at the 10% w/w level in F5.  
 
Figure 18 Results of in vitro dissolution test. Drug release profiles within 120 s 
of paracetamol lipid microspheres between 160-200 mesh with different 
contents of Eudragit E100 (▴: Paracetamol; ■: 0% Eudragit E100; ▲: 3.2% 
Eudragit E100; -: 5.0% Eudragit E100; ×: 7.5% Eudragit E100; ●: 10.0% 
Eudragit E100; n = 6) 
Detailed data of percentage drug dissolution at 10 and 30 s were shown in 
Table 7.  These time periods were selected according to the average 
swallowing time in humans, therefore the amount of drug released after 10 s 
and 30 s was a key factor when considering and comparing the taste masking 
potential of the test formulations. From this analysis, the microspheres (160-200 
mesh) containing 10% w/w Eudragit E100 provided the optimal system in vitro, 
demonstrating a zero-order release model with less than 2% paracetamol 
released after 30 s. 
 89 
 
Table 7 Results of dissolution test at 10 and 30 seconds Time (s) 
 Drug Release Percentage of Different Formulations (%) 
 API F1 F2 F3 F4 F5 
10 31.2 5.8 0.3 0.9 0.8 0 
30 70.9 24.7 8.9 9.7 9.7 1.2 
API: paracetamol bulk drug; F1-F5: paracetamol taste masking lipid 
microspheres formulations described in Table 6 
3.1.3.3 X-ray powder diffraction 
In order to compare the XRD spectrum of various samples, the raw data of XRD 
were re-drawn by Excel (Version 2010, Microsoft, America). Figure 19A shows 
that the paracetamol and octadecanol were crystalline solids while Eudragit 
E100 was amorphous.  
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Figure 19 Results of XRD. 19A XRD spectrums of octadecanol (red), 
paracetamol (blue) and Eudragit E100 (green); 19B and 19D XRD spectrums of 
dissolution samples of F1 at 0 min (blue), 5 min (red), 60 min (green) and 
normalized spectrums of three samples at 2θ of 23.5°; 19C and 19E XRD 
spectrums of dissolution samples of F5 at 0 min (blue), 5 min (red), 60 min 
(green) and normalized spectrums of three samples at 2θ of 23.5°  
The spectrums of samples after dissolution test at 0, 5, and 60 min of F1 and F5 
are shown in Figure 19B and Figure 19C, respectively. It is well known that the 
intensities of XRD peaks are related to the loading amounts of samples. 
Therefore, the characteristic peaks for paracetamol were normalized to 
invariable peaks of octadecanol which was insoluble in the dissolution medium. 
The characteristic peaks at 2θ of 23.5° for paracetamol (Figure 19D and Figure 
19E) was selected for relative quantification because the characteristic peak at 
2θ of 24.5° overlapped with that of octadecanol. 
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The relative quantification showed that the paracetamol released rapidly from 
octadecanol based microspheres and Eudragit E100 significantly inhibited the 
release of paracetamol within 5 min, while the paracetamol almost completely 
released at 60 min from both formulations. The results of XRD test 
demonstrated the crystal forms of materials in the microspheres and illustrated 
the release behaviours of various formulations, which were in accordance with 
dissolution test and were supportive to the SR-μCT results from another 
perspective. 
3.1.3.4 SR-μCT 
During the drug dissolution test, three representative samples were selected for 
SR-μCT study, taken from the dissolution medium at 0, 5 and 60 min, which 
represented non-released, partly-released and completely-released drug 
samples, respectively.  
Paracetamol of F1 without Eudragit E100 was released more rapidly than that 
of F5 with 10% Eudragit E100 and both F1 and F5 had completely released at 
60 min (Figure 20). It is demonstrated that the release behaviour of 
microspheres with fraction size between 80-100 mesh was similar to those 
between 160-200 mesh. Therefore, the structural characteristics of both size 
fractions were also similar, which can be characterized by the SR-μCT 
investigation. 
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Figure 20 Results of in vitro dissolution test. Drug release profiles within 60 min 
of paracetamol lipid microspheres between 80-100 mesh with different contents 
of Eudragit E100 (▴: 0% Eudragit E100; ■: 10.0% Eudragit E100; n = 6) 
3.1.3.4.1 2D monochrome X-ray CT images 
Images were processed to reduce noise and enhance the contrast. All 
radiograph images were normalized based on the intensity within the selected 
rectangular reference region which was never occluded by the sample in any of 
the images for the correction of varied illumination, and a simple median 
smoothing filter was performed for the noise reduction. During the TIE-Hom 
phase retrieval, zingers filter has been applied to remove isolated pixels or 
small clusters of pixels in which the signal was much higher than that in the 
surrounding part of the input frame files or dark and flat field files for the 
correction of artefacts. Brightness, contrast and gamma settings were also 
adjusted for the contrast enhancement of reconstructed slices. After the 
optimization, the crystal particles of paracetamol could be distinguished from 
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the excipients due to the noise reduction and phase retrieval. The grey value of 
the background was closed to 0, while the excipients were between 60-140 and 
the crystal particles gave a grey value above 145. The bright/white areas in 
Figure 21 represented crystal particles and the octadecanol were seen as the 
grey areas. 
 
Figure 21 2D monochrome X-ray CT images of paracetamol microspheres (F1 
and F5) at different sampling time (A, B and C are images of F1 at 0, 5 and 60 
min; D ,E and F are images of F5 at 0, 5 and 60 min) 
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The 2D monochrome X-ray CT images of paracetamol lipid microsphere of F1 
and F5 at different sampling time (0, 5 and 60 min) were shown in Figure 21. 
From Figure 21A and 21D, it was clear that the white zones, which were the 
paracetamol crystals, were randomly distributed in the microspheres. The size 
and shape of the paracetamol crystals were quite different from each other. A 
number of crystals had irregular or needle like shapes, and in some cases, a 
sharp segment partly exposed on the surface of microspheres. There were also 
some small voids within microspheres which were believed to be air bubbles 
resulting from the rapid stirring of the liquid phase prior to spraying in the 
microsphere formation process. The presence of the bubbles was more 
pronounced for the microspheres containing Eudragit E100 (Figure 21D) as a 
consequence of dramatically increased viscosity of the liquid phase during 
stirring, which retained the bubbles during further processing. 
The voids, shown in Figure 21B and Figure 21E, demonstrated that the 
paracetamol crystals had been gradually dissolved. Most of these voids were 
located on the surface of the microspheres and in shape similar to those drug 
crystals, indicating that the sharp protuberances part of crystals might be well 
enveloped by octadecanol and the crystals exposed on the surface dissolved 
quickly after being soaked with the dissolution medium. Paracetamol in 
microspheres without Eudragit E100 dissolved faster than that with 10% 
Eudragit E100. It is well known that Eudragit E100 is water-insoluble with 
excellent film-coating function as a kind of coating material. Thus, it could inhibit 
the release of paracetamol from microspheres, which was the key factor to 
mask the bitter taste of paracetamol in the mouth for a period of time. 
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The images in Figure 21C and Figure 21F showed that all the paracetamol had 
been practically dissolved after 60 min regardless of the presence or absence of 
Eudragit E100 in the formulation. This finding demonstrated that the polymeric 
additive would not inhibit the release of the drug to such an extent that drug 
release and in vivo absorption would be inhibited whilst providing the potential 
of taste masking over a sufficient long period of time.  
3.1.3.4.2 Visualization of the internal 3D structure 
From analysis of grey values, X-ray CT data from all of the microspheres in the 
samples were examined. Highly resolved tomographic images of drug crystals 
and voids in the microspheres after different periods of dissolution test with high 
quality phase contrast were then derived after 3D reconstructions. Based on the 
difference of grey value, the matrix of octadecanol and paracetamol crystals in 
the microspheres had been segmented and extracted respectively. Then, the 
constructed 3D models of matrices and crystals were colored with different color 
maps (for matrices, autumn varied smoothly from red, through orange, to yellow; 
for crystals, jet ranges varied from blue to cyan, yellow, orange and red, 
indicating the density from low to high) and merged together to show the 
relative distributions. The morphology and changes over the release phase of 
all crystals had been shown with the extracted 3D models (Figure 22 and 23). 
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Figure 22 3D X-ray CT images of paracetamol microspheres (F1) at different 
sampling time (A, B and C are images of F1 at 0 min; D, E and F are images of 
F1 at 5 min; G, H and I are images of F1 at 60 min; A, D and G are ISO Surface 
images of complete microspheres; B, E and H are images of microspheres 
partly split; C, F and I are images of paracetamol crystals extracted from 
microspheres). Nothing could be seen in image I, because all of the drug 
crystals have dissolved. 
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Figure 23 3D X-ray CT images of paracetamol microspheres (F5) at different 
sampling time (A, B and C are images of F5 at 0 min; D, E and F are images of 
F5 at 5 min; G, H and I are images of F5 at 60 min; A, D and G are ISO Surface 
images of complete microspheres; B, E and H are images of microspheres 
partly split; C, F and I are images of paracetamol crystals extracted from 
microspheres). Nothing could be seen in image I, because all of the drug 
crystals have dissolved. 
The reconstructed 3D tomographic images of paracetamol microspheres 
demonstrated that the 3D morphology and distribution of paracetamol crystals 
embedded in the microsphere were highly variable (Figure 22 and Figure 23). 
Both irregular, small crystals and long needles were identified mostly embedded 
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in the microsphere. However, a few small particles and segments of several 
needle-shaped crystals exposed to the surface of microspheres. Therefore, 
some protuberances of paracetamol crystals were observed on the surface of 
microspheres as the red arrows indicated. Comparison between Figure 22A and 
Figure 23A indicated that before being soaked in the dissolution medium, the 
original surface of F5 microspheres was smoother than that of F1, due to more 
hollows and protuberances distributed on the surface of F1 microspheres. This 
should be the results of the addition of Eudragit E100 in the formulation to 
increase the viscosity of F5 mixture and influence the ejection process of 
droplets. The illustrations also showed the surface morphology and internal 
structural changes of different formulations of paracetamol microspheres after 
dissolution test. A number of voids distributed around the surface of 
microspheres and complex interconnecting tunnels were found throughout the 
microspheres (Figure 22D-I and Figure 23D-I). These findings provided a 
structural evidence to support the interpretations of drug release profiles 
discussed above. It was concluded that at the early stage of the dissolution 
process, exposed paracetamol crystals and segments of the needle crystals 
dissolved rapidly to leave voids, and then the voids gradually became larger 
and finally integrated with each other to generate interconnected tunnels. The 
images also showed that all of the paracetamol crystals had been dissolved or 
released from the tunnels at 60 min (Figure 22I and Figure 23I). 
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Figure 24 Transparent 3D ISO surface model of paracetamol microspheres at 
different sampling time (A is the image of F1 at 0 min; B is the image of F1 at 5 
min; C is the image of F1 at 60 min; D is the image of F5 at 0 min; E is the 
image of F5 at 5 min; F is the image of F5 at 60 min) 
The transparent 3D ISO surface models showed the surface morphology, the 
distribution of voids on the surface and the internal tunnels in the microspheres 
(Figure 24). The original surface of F5 exhibited a smoother surface and inner 
voids, which might result from the presence of Eudragit E100 with high viscosity 
and strong film-forming property (Figure 24A and Figure 24D). After 5 minutes 
dissolution, the crystals on the surface and crystals with protuberances exposed 
on the surface were dissolved and voids with different depths inside were 
generated. Compared with F1, the voids in F5 were separated with each other. 
It was hypothesized that small sized crystals and angular segments of larger 
crystals on the external surface were completely covered by the Eudragit E100 
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during processing. Voids formed tunnels and thus internally located and 
embedded crystals could contact with the dissolution medium. 
 
Figure 25 Size distributions of all the pores on the surface of microspheres after 
dissolution test for 60 minutes (three microspheres had been calculated for 
each formulation; dotted columns are F1; slashed columns are F5) 
However, the voids on the surface of F1 microspheres were obviously larger 
than those of F5, which was also the same after 60 minutes dissolution with 
complete release of the paracetamol. In order to quantitatively evaluate the 
microstructure of the surface, the void diameter distributions have been 
calculated. All voids distributed on the surface were measured manually with 
the 3D reconstructed model (Figure 22G and Figure 23G) and three 
microspheres for each formulation had been calculated. The results showed 
significant difference between the two formulations (Figure 25), for which the 
mean void diameter of F5 had a smaller value of 30.81 μm, while the average 
void diameter of F1 was 39.51 μm. The wider distribution range of F1 indicated 
the higher morphological irregularity of the voids. This observation was 
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attributed to Eudragit E100, as the insolubility of Eudragit E100 would lead to a 
reduction in the degree of hydration and extent of erosion.  
After 60 minutes in the dissolution medium, numerous tunnels in the 
microspheres were interconnected and reached to the surface. The total void 
volume of F1 and F5 were similar, but voids on the surface of F1 were larger in 
dimension than F5, indicating that without Eudragit E100 the erosion degree of 
octadecanol was higher. 
These results indicated that an appropriate size of drug crystals is one of the 
important factors for taste masking for the hydrophobic matrix based 
microspheres. The oversize crystals of drug raw material are disadvantageous 
to the coating and coverage by octadecanol and Eudragit E100 generating large 
tunnels, while the undersized crystals have high dissolution rate, both of which 
increase free drug concentration in medium or saliva to bring about bitter taste. 
Besides, the addition of hydrophobic materials with high viscosity, such as 
Eudragit E100, could significantly benefit taste masking, which is helpful to coat 
the drug crystals as well as inhibits the release of drug because of its low 
hydration rate. 
3.1.3.4.3 Correlation between structural parameters and drug release 
Three microspheres were randomly selected for quantitative analysis of drug 
content by SR-μCT. The volume ratio of paracetamol in the microsphere had 
been calculated by segmenting and extracting different materials based on 
phase contrast images.  
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The tested volume ratio of paracetamol in microspheres before dissolution test 
(0 min), described as RV0, which can be obtained from Eq. 26: 
EudEudOctOctAceAce
AceAce
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                                                          (26) 
where M is the mass of various materials in microspheres before dissolution 
test, and ρ is the density of materials (Ace: Paracetamol, Oct: Octadecanol, Eud: 
Eudragit E100).  
After dissolution testing, the volume ratio of paracetamol in the released 
microsphere (RV1) can be obtained from Eq. 27:  
 EudOctAceAceV VVVVR 11111                                                                             (27) 
where V1 is the volume of various materials in released microspheres, which 
could be calculated by Image Pro analyzer 3D.  
Also, RV1 can be calculated from Eq. 28: 
   VRVRVV RRRR  101                                                                                   (28) 
where RVR is the volume ratio between released paracetamol and the total 
volume of microsphere before dissolution test. Here, it is assumed that Eudragit 
E100 and octadecanol are insoluble in distilled water. Therefore, RVR can be 
obtained by combining Eq. 27 with 28. 
The tested volume ratio between volume of released paracetamol and volume 
of original paracetamol (RVT) is equal to release percentage (R), which can be 
obtained from Eq. 29. 
0VVRVT RRRR                                                                                               (29) 
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Table 8 Comparison of tested and calculated values of drug content and 
release for F1 and F5 at 0, 5 and 60 min 
Formulations 
Drug content at 
0 min (%) 
Drug Release Percentage (%) 
5 min 60 min 
F1 Tested 23.9 53.8±3.0 98.2±2.5 
Calculated by SR-μCT 20.9±2.3 51.7±1.4 99.0±1.4 
F5 Tested 21.2 27.3±2.3 99.6±3.0 
Calculated by SR-μCT 17.9±0.8 28.0±4.6 98.4±3.0 
The “Calculated by by SR-μCT” drug release percentages for 5 and 60 min 
were measured by SR-μCT, while the “Tested” drug release percentages for 5 
and 60 min were determined by dissolution test. Drug contents in the 
microspheres at 0 min for “Tested” and “Calculated by SR-μCT” are the volume 
ratio of the Paracetamol in the microspheres before dissolution test, which were 
obtained by formula and SR-μCT measurement, respectively. F1: paracetamol 
taste masking lipid microspheres without Eudragit E100; F5: paracetamol taste 
masking lipid microspheres with Eudragit E100 (10%, w/w). 
From data in Table 8, it was clear that the drug content and release values 
measured by SR-μCT were in good agreement with experimentally determined 
data, which demonstrated that SR-μCT can distinguish various materials and 
accurately calculate their volume in multicomponent microspheres.  
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3.2 Chemical Distribution on Surface of Taste Masking 
Lipid Microspheres as Determined by SR-FTIR 
In the pharmaceutical sciences, membranes play important roles in masking 
undesirable tastes. High coating weight is necessary for conventional coating 
technologies for taste masking, especially for small particles, such as 
microspheres. Layer-by-layer (LBL) is a flexible coating method to fabricate 
functional films with precise control of chemical composition and architecture on 
micro- and nanoscales [173, 174]. This method involves alternative adsorption 
of oppositely charged polyelectrolytes on substrates. The molecular and 
interactive multilayers might have important value in control release and taste 
masking for drugs. In my research, ibuprofen lipid microspheres prepared by 
octadecanol could mask the bitter taste of the drug to some extent, which were 
further coated with chitosan (cationic) and gelatin (anionic) by Layer-by-Layer 
method. LBL films will be applied in modification of the surface of lipid 
microspheres to obtain satisfactory taste masking effects. 
Most reported research into membrane has used scanning electron microscopy 
(SEM) for observing the structural changes of membranes [175-177]. 
Combining SEM data with FTIR and differential scanning calorimeter (DSC) 
techniques, characterization of the effects of the membrane preparation 
methods on the in vitro release of theophylline through CA membranes has 
been attempted [178]. With the development of imaging and spectroscopic 
techniques for the quality control of pharmaceutical products, three-dimensional 
terahertz pulsed imaging and terahertz time-domain reflection signals have also 
been applied to investigate coating characteristics of membranes, detecting the 
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influence of internal physical alterations to the drug release kinetics and 
obtaining information on both the spatial distribution of the coating thickness 
and physical alterations impacting the drug release [179]. Magnetic resonance 
imaging and relaxometry have also been applied to study water transport 
mechanisms in a commercially available gastrointestinal therapeutic system 
tablet [180]. Quartz crystal microbalance (QCM) was used to investigate the 
interaction between anion and cation by measuring shift of crystal oscillator 
frequency among deposition of each layer to confirm the fabrication of LBL films 
[181]. However, these reported techniques for examining the structural changes 
of membranes failed to reveal the spatial chemical distribution simultaneously. 
FTIR spectroscopy is widely employed to determine the molecular structure and 
chemical composition of a given sample [182]. Compared with a conventional 
standard Globar IR source commonly used in an offline laboratory-based FTIR 
microspectroscopic instrument, the highly collimated synchrotron radiation 
based FTIR (SR-FTIR) beam essentially offers 100-1000 times higher 
brightness (defined as the photon flux or power emitted per source area and 
solid angle) [183]. The SR-FTIR microspectroscopy and imaging are able to 
provide a higher signal-to-noise ratio at high spatial resolutions and allow for 
smaller regions within a specimen to be analyzed [184]. Recently, SR-FTIR has 
been developed as a rapid, direct and non-destructive chemical microprobe with 
high flux and brightness, and high coherence. SR-FTIR has also been 
successfully used as a powerful tool to reveal internal chemical structure 
changes at a cellular or subcellular dimension among various food/ feed and 
plant/seed tissues [185-188], as well as the quantitative measurement of the 
distribution and localization of protein/peptide constituents within a single 
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microsphere made of poly-lactide-coglycolide [189]. Following a thorough 
literature search, no reports on the direct observation of the chemical 
distribution in the LBL membranes could be identified. Thus, the existence and 
distribution of the drug and material of coated film have been determined using 
SR-FTIR to provide deep understanding of LBL membranes. 
3.2.1 Materials 
Ibuprofen with purity of 99.9% was provided by Baikegelai Pharmaceutical Co., 
Ltd., China; chitosan and gelatin were purchased from Jinke Pharmaceutical 
Excipients Co., Ltd., China；paraffin was purchased from Sinopharm Chemical 
Reagent Co., Ltd., China. The Synchrotron radiation FTIR mapping scans were 
carried out at the Shanghai Synchrotron Radiation Facility (SSRF) in Shanghai 
Institute of Applied Physics, Chinese Academy of Sciences (Shanghai, China). 
Data were analyzed using the commercially available software OMINIC (9.2.86 
Thermo Fisher Scientific, Inc.) and Matlab (R2012a，Math Works, Inc.). 
3.2.2 Methods 
3.2.2.1 Preparation of ibuprofen lipid microspheres 
Ibuprofen lipid microspheres were prepared by the addition of an appropriate 
amount of Ibuprofen into octadecanol at 60 oC (1:2, w/w) whilst stirring the 
system at 1000 rpm to obtain a uniform fusion. The mixture was then 
immediately poured into the reservoir of a spray gun preheated to 70 oC in a 
drying oven and sprayed such that the air dried microspheres at room 
temperature were collected from stainless steel trays for further research.  
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3.2.2.2 Preparation of polyelectrolyte coated ibuprofen lipid microspheres 
The ibuprofen lipid microspheres were coated with polyelectrolytes by layer-by-
layer assembly using vacuum filtration system. The ibuprofen lipid microspheres 
were placed on gauze or filter paper with Buchner funnel. The Buchner funnel 
was stopped during the polyelectrolyte adsorption period to ensure consistent 
contact of polyelectrolyte solution and microspheres. Afterwards vacuum 
pumping was used to remove the polyelectrolyte solution. 
Firstly, the chitosan layer was deposited with addition of chitosan 1% acetic acid 
solution (1% w/v) into the Buchner funnel. The mixture was then incubated for 
0.5 min. Thereafter, the next layer of gelatin (type B with the isoelectric point 
about 4.5-5.6) water solution (1% w/v) was deposited using the same procedure. 
The above two steps were identified as „one cycle‟. Subsequent alternating 
chitosan and gelatin layers were deposited in an identical way until the desired 
number of chitosan/gelatin cycles was achieved. Following this the coated 
samples were oven dried at 40 ºC for 2 h. Control samples were prepared that 
contained only chitosan or gelatin solutions (both 1% w/v) cycled with the same 
number of coating layers as used with the LBL method.  
3.2.2.3 Short term in vitro drug release test 
Short term in vitro drug release tests were conducted in an incubator shaker 
(ES-60+, Miu Instruments Co., Ltd., China). As a mimic of the microenvironment 
of the human oral cavity, the release medium selected was buffer (5mL, pH 7.2) 
and it was monitored at 15, 30 and 60 s. The temperature of the release 
medium was maintained at 37 ± 0.5 °C and the rotation speed of the incubator 
shaker was 100 rpm. Aliquots of samples (0.5 mL) were withdrawn at the set 
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times and replaced with equivalent volumes of fresh medium. The samples 
withdrawn were filtered (0.22 μm porous membrane filter) and analyzed using a 
high performance liquid chromatograph system (1260, Agilent, Palo Alto, USA) 
consisting of a binary pump (G1311C), an auto-sampler (G1329B) and a diode 
array detector (G4212B). The separation was achieved on a Diamonsil C18 
column (5 μm, 150 mm × 4.6 mm) at 40 °C. The mobile phase consisted of 
sodium acetate buffer (7 mM, pH2.5): acetonitrile (40:60, v/v) and flow rate 1.0 
mL/min. A calibration graph showed that the linear concentration range for was 
0.5 - 75.0 μg/mL (R = 0.9999). Repeat in vitro experiments were carried out (n= 
6). 
3.2.2.4 Processing of membranes for SR-FTIR 
The uncoated microspheres, microspheres coated with 80 layers of chitosan, 
microspheres coated with 80 layers of gelatin and microspheres coated with 80 
cycles of chitosan and gelatin were poured into melting paraffin and then 
cooling. Paraffin-embedded samples were sectioned into 10-μm-thick sections. 
The LBL membrane powder sample was peeled by gently scraping the surface 
of microspheres coated with 80 cycles of chitosan and gelatin (as described in 
section 3.2.2.2) using a razor blade. 
3.2.2.5 SR-FTIR microspectroscopy and imaging 
SR-FTIR microspectroscopy was performed with the BL01B beamline at SSRF 
(Shanghai Synchrotron Radiation Facility). Spectra of the samples were 
recorded on a Nicolet Continuμm XL microscope (ThermoFisher Scientific, Inc.) 
equipped with a 250× 250 μm2 liquid nitrogen cooled MCT/A detector, a 
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32X/NA0.65 Schwarzschild objective, a motorized knife-edge aperture, and a 
Prior XYZ motorized stage and coupled with Nicolet 6700 spectrometer 
(Thermo Fisher Scientific, Inc.) equipped with a Michelson interferometer. 
Following sample preparation using KBr tableting, FTIR spectra of chitosan, 
gelatin, octadecanol and ibuprofen were recorded in transmission mode 
between 600 cm−1 and 4000 cm−1, with 128 scans at 4 cm−1 resolution, and 10 
μm × 10 μm aperture dimension.  
The cross section of paraffin-embedded microspheres were mapped on the 
BaF2 substrate and scanned in transmission mode between 600 cm
−1 and 4000 
cm−1, with 64 scans at 4 cm−1 resolution, aperture dimension was set at 10 μm 
× 10 μm. With step size of 10 μm, totally spectra of 20 × 18 points were 
captured. 
3.2.3 Results and discussion 
3.2.3.1 Short term in vitro drug release 
It could be observed that ibuprofen released more slowly from coated 
microspheres than uncoated microspheres. And the optimal sustained-release 
behaviour was observed for microspheres coated by 80 cycles of chitosan and 
gelatin, indicating unpleasant taste could be masked by microspheres coated by 
LBL membranes (Figure 26).  
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Figure 26 The release profiles of microspheres coated with different materials in 
PBS pH 7.2 (▴: Gelatin, ■: Gelatin and chitosan, ▲: Chitosan and ╳: Lipid 
microspheres without coating) 
3.2.3.2 Specific bands of SR-FTIR spectra 
Chitosan, gelatin, ibuprofen, octadecanol and the membranes powder samples 
were characterized by SR-FTIR (Figure 26). For the spectra of ibuprofen, the 
absorption peak at 1723 cm−1 corresponded to the C=O stretching vibration. For 
the spectra of octadecanol and chitosan, 1462 cm−1 and 1653 cm−1 were 
characteristic peaks of these compounds respectively. The band at 1548 cm−1 
corresponded to the amide Ⅱ infrared band, which could be identified as a 
characteristic peak of gelatin. 
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Figure 27 Following spectral bands were identified, ibuprofen, 1713-1733 cm-1 
(C=O bond); octadecanol,1452-1472 cm-1 (-CH2 bond); chitosan; 1590-1610 
cm-1 and 1650-1670 cm-1; gelatin, 1538-1558 cm-1 and 1643-1663 cm-1 (amide 
band).  
The characteristic absorption of gelatin and chitosan could be observed in the 
membrane powder, from the surface of the particles and the film, which are 
primarily responsible for taste masking effect. 
Absorption peaks at 1538-1558 cm-1 and 1650-1670 cm-1 were observed for the 
membrane peeled from the surface of LBL coated microspheres, which might 
indicated that gelatin and chitosan were deposited on the surface of 
microspheres by LBL coating.  
3.2.3.3 Analysis of SR-FTIR mapping 
Results in Figure 28 show that SR-FTIR scans reveal significant differences 
from inside to the outside surface of microsphere (1-14 scanning points). In 
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particular, specific peaks of gelatin and chitosan could not been observed in the 
interior of microspheres (1-12 scanning points). Data extracted from mapping 
image demonstrated that the absorptions of chitosan and gelatin existed on the 
surface of the coated microspheres. As the scanning progressed to the edge of 
the microsphere cross section (13 scanning points), specific intense peaks of 
gelatin and chitosan were observed (see Figure 28). At the 14 scanning point, 
specific peak (double peaks) of gelatin could be observed (Figure 28). It was 
confirmed that as scanning from the interior to the surface, the ibuprofen 
signature remained unchanged but decreased in intensity near the surface film. 
At the surface of the microspheres, both of drug and excipients can be 
distinguished, because the spatial resolution of mapping was 10 μm which was 
limited by the size of light spot (10 μm*10μm), while thickness of film might be 
less than 10 μm. 
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Figure 28 Synchrotron radiation-based Fourier-transform infrared spectra of 14 
scanning points (numbered from inside to outside of microspheres as 1 to 14) 
gelatin 
For the microspheres coated with 80 cycles of chitosan and gelatin, the 
mapping was analyzed using OMNIC software (ThermoFisher Scientific 
Company) to get the integral distribution of chitosan and gelatin. Integral 
distribution showed the evidence for existence and the location of chitosan (a) 
and gelatin (b) (Figure 29). The distribution of chitosan and gelatin 
characterized as a band absorption showing a section of the sliced film. Neither 
chitosan nor gelatin could be observed inside or outside of the microspheres, 
both compounds only appearing on the microsphere surface (Figure 29). The 
results show that chitosan and gelatin were deposited on the microsphere 
surface and formed a film to the benefit of taste masking the microsphere 
entrapped ibuprofen. 
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Figure 29 Distribution of chitosan and gelatin as determined by integral 
distribution map. a: The integral distribution map gained from the specific peak 
of chitosan in scanning area; b: The integral distribution map was obtained from 
the specific FT-IR peak of gelatin in the scanned area. The red outlined areas 
for (a) and (b) (left image) indicate the area imaged by synchrotron radiation-
based. The Fourier-transform infrared spectromicroscopy integral distributions 
of chitosan or gelatin (right images) 
After data smoothing and automatic baseline correction, the ratio map analysis 
was carried out by MATLAB. From ratio mapping of gelatin (1590-1610 cm-1) / 
octadecanol (1452-1472 cm-1) and chitosan (1643-1663cm-1) / octadecanol 
(1452-1472cm-1), the absorption band distributed along with the microsphere 
surface confirming the presence of gelatin and chitosan on the film (b and c). In 
contrast chitosan and gelatin could not been clearly observed in microspheres 
coated only by chitosan (d) or gelatin (e) (Figure 30). Further, for chitosan, the 
weak FT-IR absorbance in the map indicates a limited amount of adhesion on 
the surface probably as a result of the high viscosity of chitosan. The ionic 
interaction of ibuprofen with gelatin and chitosan made possible by the layer-by-
layer coating procedure will facilitate entrapment of the bitter tasting drug within 
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the microsphere. The net result is prevention of ibuprofen release with 
concomitant masking of the unpleasant taste of ibuprofen formulated in this way. 
 
Figure 30 Chemical distributions by ratio analysis showing intensity map of 
gelatin and chitosan within microspheres (red most intense distribution, dark 
blue least intense distribution). b: Distribution of chitosan obtained by ratio 
between chitosan/octadecanol on the microspheres coated with gelatin and 
chitosan; c: Distribution of gelatin obtained by ratio between gelatin/octadecanol 
on the microspheres coated with gelatin and chitosan. d: Distribution of chitosan 
obtained by ratio between chitosan/octadecanol on the microspheres coated 
with chitosan. e: Distribution of chitosan obtained by gelatin / octadecanol on 
the microspheres coated with gelatin. The red boxes indicated the area imaged 
by synchrotron radiation-based Fourier-transform infrared spectromicroscopy 
(left); distributions of chitosan or gelatin (right). 
The results indicate that ibuprofen formulated as lipid microspheres prepared by 
melting method (see section 3.2.2.1) does effectively entrap this drug and could 
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therefore help mask ibuprofen‟s unpleasant taste. Coating the lipid 
microspheres with chitosan (cationic) and gelatin (anionic) using a layer-by-
layer self-assembly (LBL) coating should further support entrapment of 
ibuprofen facilitating further a bitter taste masking effect. The release 
percentage of drugs in short time (1 min) was utilized as an indicator for the 
taste-masking, and it confirmed the LBL coating inhibited the release of model 
drug of ibuprofen.  
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Chapter 4 Conclusions 
 
The presented research has established a relationship between association and 
dissociation rates (as measured by Ka and Kd respectively) and bitter taste 
masking of drugs complexed with cyclodextrins. Using both SPRi and HPAC 
methodologies to determine Ka, Kd and their derivative constants allowed the 
development of a model useful to the prediction of bitter taste masking. More 
specifically the results successfully established a relationship between the 
kinetic interactions of HP-β-CD complexed with a panel of drugs and generated 
model data which was proved sufficiently accurate by 10-fold cross-validation. 
The relationship model could be used to predict the bitter taste masking of 
drugs more generally. The model provided basis and strategy to taste masking 
formulation design by drug-CD inclusions. On the other hand, HPAC method 
was also used to investigate the relationship between taste masking effects and 
kinetic constants between drugs and cyclodextrins, by which the model was 
established and similar to that established by SPRi in a great extent. The results 
demonstrated that both of the two methods could be used to investigate and 
provide new vision that the molecular kinetic interaction between cyclodextrins 
and bitter drugs could be correlated with the taste masking effects. The model 
based on SPRi showed better accuracy and precision in comparison with HPAC 
due to the intrinsic and different properties of the two methods, namely, drugs or 
cyclodextrins immobilized on stationary phase influenced binding interactions. 
There were also other limits, such as organic solvents and flow rate of mobile 
phase, for the applications of HPAC. At the same time, the relationship of taste 
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masking and host-guest kinetic interaction of cyclodextrins and bitter drugs was 
further successfully applied to optimize formulation.   
As for microstructure, SR-μCT and SR-FTIR were utilized to investigate the 
relationship of fine microstructure of microsphere and mechanism of taste 
masking. As a powerful structural characterization tool, SR-μCT was used to 
study the internal fine structure of the paracetamol loaded microspheres and the 
calculated amounts of drug released, revealing the primary influence of Eudragit 
E100 on particle morphology, structure and taste masking effects. Quantitative 
structure analysis indicated that precise evaluation of the changes in fine 
structure for particle formulations could contribute to explain the mechanism 
and illustrate the structural change during a short period of time to simulate the 
taste masking. Thus the analysis provided knowledge and deep understanding 
of the role of particle morphology and their structural assembly in microspheres 
for a rational design and manufacturing taste masking products. On the other 
hand, SR-FTIR has been applied to investigate the material distributions on the 
cross section of microspheres and film coating. Characteristic absorptions of the 
compositions were obtained by SR-FTIR single spectrum scanning. The 
distributions of the drug and materials in coated films were determined by SR-
FTIR mapping. The FTIR absorptions of chitosan and gelatin on the surface of 
lipid microspheres were examined to verify the deposition of chitosan and 
gelatin on the surface and film formation using SR-FTIR ratio analysis. Whilst 
microspheres coated only by chitosan or gelatin did not show the characteristic 
absorption peaks, which confirmed the effects of ionic interaction on the film 
formation process. Therefore, the method of SR-FTIR established for the study 
of distribution of materials in coated film provided a new choice for researches 
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on membranes/films in taste masking drug delivery systems and 
pharmaceutical preparations. 
In conclusion, this research illustrates the relationships between bitter taste and 
molecular interactions and structures from micro scales, namely, molecular 
kinetic basis of interaction between bitter drugs and CD as well as 
microstructural basis of particles formulation for taste masking. Novel 
methodologies and strategies based on SPRi and SR are provided to 
investigate bitter taste masking from molecular interactions and microstructures, 
deepening knowledge and view to understand and formulations design for taste 
masking. 
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Appendix 
 
SPRi Data of interactions between 485 drugs and HP-β-CD 
Drug name Ka(1/Ms) Kd(1/s) K(1/M) 
Azaguanine-8 4810 1.03E-05 4.69E+08 
Meticrane 7660 1.94E-04 3.95E+07 
Minoxidil 1290 4.57E-05 2.82E+07 
Khellin 5960 1.06E-04 5.63E+07 
Zimelidine 3980 4.01E-05 9.93E+07 
Azacyclonol 2800 8.34E-05 3.35E+07 
Lynestrenol 1690 3.63E-05 4.66E+07 
Guanabenz 54.6 1.62E-04 337000 
isulfiram 1330 1.29E-04 1.04E+07 
Acetylsalicylsalicylic acid 569 1.00E-04 5.68E+06 
Amoxapine 1130 5.12E-05 2.20E+07 
Cyproheptadine 67.7 1.17E-04 577000 
Danazol 1230 1.39E-04 8.85E+06 
Pioglitazone 1470 1.54E-04 9.54E+06 
Dizocilpine 8470 2.93E-05 2.89E+08 
Triamterene 54.5 1.39E-04 391000 
Dapsone 61 9.04E-05 675000 
Pyrimethamine 218 1.49E-04 1.46E+06 
Diflunisal 1360 1.70E-04 8.01E+06 
Niclosamide 1500 8.69E-05 1.73E+07 
Metolazone 8.61 5.29E-05 163000 
Naproxen 337 7.24E-05 4.66E+06 
Ticlopidine  1880 6.18E-05 3.05E+07 
Dicyclomine  39.3 7.05E-05 558000 
Amyleine  1600 2.97E-05 5.38E+07 
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Amfepramone  102 1.26E-04 813000 
Dehydrocholic acid 7120 9.63E-05 7.39E+07 
Tioconazole 718 8.26E-05 8.69E+06 
Perphenazine 437 1.33E-04 3.30E+06 
Isoconazole 4940 9.49E-05 5.20E+07 
Spironolactone 37.2 1.65E-04 226000 
Dexamethasone 735 1.72E-04 4.26E+06 
Carbamazepine 89.2 1.25E-04 717000 
Triflupromazine  134 1.54E-04 869000 
Mefenamic acid 3820 1.21E-04 3.15E+07 
Acetohexamide 575 1.25E-04 4.62E+06 
Chlorpromazine  1100 0.00172 640000 
Diphenhydramine  115 0.00172 66900 
Miconazole 2.55 0.00175 1460 
Isoxsuprine  2680 0.00171 1.57E+06 
Tolnaftate 3740 0.00165 2.26E+06 
Verapamil  17800 0.00168 1.06E+07 
Nicergoline 2170 1.03E-04 2.11E+07 
Dihydroergotamine 4450 3.96E-05 1.12E+08 
Riluzole  2450 3.12E-05 7.86E+07 
Flavoxate  5380 1.63E-05 3.31E+08 
Norethindrone 502 1.27E-05 3.96E+07 
Nortriptyline  2370 1.00E-04 2.37E+07 
Niflumic acid 110 3.79E-06 2.91E+07 
Isotretinoin 80.1 2.07E-05 3.87E+06 
Antazoline  151 1.92E-05 7.83E+06 
Ethacrynic acid 240 1.94E-05 1.24E+07 
Praziquantel 1310 2.78E-05 4.70E+07 
Levamisole  612 2.41E-05 2.54E+07 
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Catharanthine 1220 8.34E-06 1.47E+08 
Nimesulide 1460 3.38E-06 4.31E+08 
Vincamine 432 9.57E-06 4.51E+07 
Indomethacin 125 3.80E-05 3.29E+06 
Cortisone 574 1.74E-06 3.31E+08 
Prednisolone 200 2.06E-05 9.72E+06 
Fenofibrate 342 1.63E-05 2.10E+07 
Bumetanide 636 5.73E-07 1.11E+09 
Labetalol  312 1.90E-05 1.64E+07 
Flufenamic acid 1850 4.16E-05 4.44E+07 
Tolfenamic acid 1890 3.48E-05 5.44E+07 
Perhexiline 317 1.00E-04 3.17E+06 
Mebendazole 865 1.11E-04 7.78E+06 
Ketoprofen 2690 1.11E-04 2.42E+07 
Indapamide 1870 1.05E-05 1.78E+08 
Dantrolene  346 9.96E-05 3.47E+06 
Trazodone  21.3 1.04E-04 205000 
Glafenine  2660 9.63E-05 2.76E+07 
Acemetacin 4340 6.29E-05 6.89E+07 
Benzydamine  1230 5.78E-05 2.12E+07 
Fipexide  87.4 5.08E-05 1.72E+06 
Mifepristone 909 7.96E-05 1.14E+07 
Diperodon  4290 6.43E-05 6.67E+07 
Gestrinone 1360 3.64E-05 3.75E+07 
Etomidate 1180 4.11E-05 2.87E+07 
Prednicarbate 6460 3.23E-05 2.00E+08 
Iopanoic acid 1860 7.24E-06 2.57E+08 
Propoxycaine  1870 4.02E-06 4.66E+08 
Norgestimate 1890 1.61E-05 1.17E+08 
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Chlormadinone 2150 8.34E-06 2.58E+08 
Fluticasone propionate 107 1.25E-04 860000 
Proguanil  71.1 1.13E-04 629000 
Lymecycline 379 8.70E-05 4.36E+06 
Cyproterone acetate 119 9.52E-05 1.25E+06 
(R)-Propranolol  512 9.83E-05 5.20E+06 
Ciprofibrate 1180 7.66E-05 1.55E+07 
Formestane 230 9.67E-05 2.38E+06 
Benzylpenicillin 422 1.18E-04 3.57E+06 
Chlorambucil 241 9.21E-05 2.62E+06 
Homosalate 266 6.92E-05 3.84E+06 
Trapidil 48.3 5.54E-05 872000 
Tribenoside 3820 3.35E-05 1.14E+08 
Rimexolone 5870 5.90E-05 9.95E+07 
Misoprostol 3430 1.31E-05 2.62E+08 
Sulfadoxine 6700 3.14E-05 2.13E+08 
Perindopril 1670 2.20E-05 7.60E+07 
Clonixin Lysinate 1510 3.11E-05 4.85E+07 
Rifabutin 2700 2.13E-05 1.26E+08 
Parbendazole 2610 1.99E-05 1.31E+08 
Halofantrine  2800 2.33E-05 1.20E+08 
Articaine  2610 2.01E-05 1.30E+08 
Nomegestrol 2410 1.66E-05 1.45E+08 
Methyldopate  216 2.17E-06 9.93E+07 
Levocabastine  211 2.37E-06 8.94E+07 
Pyrvinium pamoate 319 3.80E-06 8.40E+07 
Saquinavir 1890 2.01E-05 9.41E+07 
Nadifloxacin 1890 1.51E-05 1.25E+08 
Buspirone  1880 2.55E-05 7.39E+07 
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Estradiol Valerate 2610 9.04E-06 2.88E+08 
Etodolac 1580 7.84E-06 2.02E+08 
Fadrozole  895 7.06E-05 1.27E+07 
Dilazep 584 7.23E-05 8.08E+06 
Ofloxacin 530 5.47E-05 9.70E+06 
Lomefloxacin  405 8.52E-05 4.76E+06 
Orphenadrine  1520 6.38E-05 2.39E+07 
Melengestrol 30.5 3.98E-05 766000 
Bromhexine  478 3.18E-05 1.50E+07 
Anethole-trithione 204 4.26E-05 4.77E+06 
Amcinonide 142 3.57E-05 3.99E+06 
Trifluoperazine 490 3.55E-05 1.38E+07 
Cefdinir 836 2.71E-05 3.09E+07 
Celecoxib 649 3.07E-05 2.11E+07 
Cladribine 2230 2.06E-05 1.08E+08 
Hexetidine 2360 2.57E-05 9.21E+07 
Pentamidine 2300 2.44E-05 9.43E+07 
Gliclazide 1140 1.59E-05 7.19E+07 
Prenylamine 2410 2.04E-05 1.18E+08 
Dipivefrin  30.4 6.65E-05 457000 
Dexfenfluramine  401 1.00E-04 4.00E+06 
Clofibrate 3050 8.99E-05 3.39E+07 
Aripiprazole 9.35 7.71E-05 121000 
Ethinylestradiol 2220 1.92E-05 1.16E+08 
Sparfloxacin 15.8 7.98E-05 198000 
Tripelennamine  427 1.14E-04 3.75E+06 
Reserpine 886 8.34E-05 1.06E+07 
Bicalutamide 39 6.19E-05 631000 
Telmisartan 383 4.18E-05 9.16E+06 
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Nalmefene  545 2.95E-05 1.85E+07 
Bifonazole 63.9 3.59E-05 1.78E+06 
Tyloxapol 348 3.18E-05 1.09E+07 
Florfenicol 9.88 3.72E-05 266000 
Deoxycorticosterone 1660 1.71E-05 9.76E+07 
Urosiol 10400 1.20E-04 8.68E+07 
Proparacaine  2560 2.27E-05 1.13E+08 
Gatifloxacin 2760 2.25E-05 1.23E+08 
Bosentan 2490 1.60E-05 1.56E+08 
Olmesartan 2420 1.73E-05 1.40E+08 
Montelukast 2210 7.73E-06 2.86E+08 
Alfuzosin  2780 2.07E-05 1.34E+08 
Chlorpropamide 2720 1.97E-05 1.38E+08 
Cefoperazone 357 6.94E-05 5.14E+06 
Tacrine  1480 4.45E-05 3.33E+07 
Testosterone 3590 3.86E-05 9.31E+07 
Haloprogin 114 8.15E-05 1.39E+06 
Thyroxine (L) 119 7.43E-05 1.60E+06 
Idebenone 2720 8.15E-05 3.34E+07 
Pepstatin A 5050 3.92E-05 1.29E+08 
Butoconazole 2100 8.35E-05 2.52E+07 
Chlormezanone 301 7.29E-05 4.14E+06 
Androsterone 232 5.44E-05 4.26E+06 
Erlotinib 3920 5.80E-05 6.76E+07 
Furosemide 298 2.64E-05 1.13E+07 
Methapyrilene  2060 7.21E-05 2.86E+07 
Desipramine  395 6.32E-05 6.25E+06 
Clorgyline  4990 1.06E-04 4.71E+07 
Thioguanosine 2270 2.61E-05 8.70E+07 
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Chlorprothixene  1460 7.78E-05 1.88E+07 
Clozapine 41.9 2.66E-05 1.57E+06 
Zotepine 7.12 2.66E-05 268000 
Cisapride 3450 5.22E-06 6.60E+08 
Pemirolast 395 2.74E-05 1.44E+07 
Droperidol 256 2.86E-05 8.96E+06 
Pefloxacine 701 2.36E-05 2.97E+07 
Corticosterone 753 2.39E-05 3.15E+07 
Cefadroxil 725 3.38E-05 2.14E+07 
Digoxin 1090 2.68E-05 4.08E+07 
Doxorubicin  933 2.94E-05 3.17E+07 
Epiandrosterone 962 2.90E-05 3.32E+07 
Betamethasone 844 3.20E-05 2.64E+07 
Colchicine 1170 2.59E-05 4.50E+07 
Metergoline 173 1.42E-05 1.21E+07 
Brinzolamide 239 1.45E-05 1.65E+07 
Ambroxol  95.5 1.27E-05 7.52E+06 
Benfluorex  520 1.49E-05 3.50E+07 
Cyclobenzaprine  3850 2.97E-06 1.30E+09 
Ketotifen 249 3.20E-05 7.80E+06 
Amethopterin (R,S) 738 2.29E-05 3.22E+07 
Methiothepin 532 2.78E-05 1.91E+07 
Clofazimine 906 2.06E-05 4.40E+07 
Nafronyl 702 2.39E-05 2.94E+07 
Bezafibrate 5220 0.0767 68000 
Nefazodone 20700 0.0721 287000 
Clebopride 18900 0.0538 351000 
Stanozolol 15500 0.0546 284000 
Calcipotriene 18200 0.0472 386000 
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Meclocycline sulfosalicylate 182000 0.0757 2.41E+06 
Meclozine 463000 0.0802 5.77E+06 
Butalbital 181000 0.0496 3.65E+06 
Lidoflazine 168000 0.0686 2.45E+06 
Betaxolol  138000 0.0546 2.53E+06 
Nicardipine  39600 0.0551 718000 
Fusidic acid 14500 5.62E-05 2.58E+08 
Indatraline  1210 1.31E-04 9.22E+06 
Ketanserin 1010 7.71E-05 1.31E+07 
Etoposide 65800 0.0612 1.07E+06 
Clomiphene citrate (Z,E) 70300 0.0704 998000 
Prochlorperazine 46800 0.0699 669000 
Hesperidin  213000 0.0787 2.71E+06 
Vatalanib 124000 0.0791 1.57E+06 
Cefotetan 936 6.94E-05 1.35E+07 
Fentiazac 4330 7.69E-05 5.63E+07 
Brompheniramine 23.6 4.80E-05 492000 
Primaquine 1790 4.76E-05 3.76E+07 
Progesterone 220 6.50E-05 3.38E+06 
Felodipine 94.1 6.94E-05 1.36E+06 
Raclopride 267000 0.0743 3.60E+06 
Benperidol 229000 0.0701 3.26E+06 
Cefaclor 359000 0.0692 5.19E+06 
Pyridostigmine 497 3.37E-05 1.48E+07 
Pentobarbital 1140 2.52E-05 4.54E+07 
Metixene  537 2.57E-05 2.09E+07 
Nitrofural 268 2.85E-05 9.38E+06 
Omeprazole 14.6 3.16E-05 462000 
Terconazole 571 2.55E-05 2.24E+07 
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Tiaprofenic acid 172 2.93E-05 5.89E+06 
Vancomycin  242 2.87E-05 8.44E+06 
Propafenone  621 8.44E-05 7.36E+06 
Tetracaine  2040 2.56E-05 7.98E+07 
Mometasone furoate 58.2 5.45E-05 1.07E+06 
Troglitazone 4340 4.39E-05 9.90E+07 
Ropinirole 1000 6.78E-06 1.47E+08 
Argatroban 1000 3.39E-06 2.95E+08 
Acenocoumarol 1820 3.36E-05 5.41E+07 
Bromperidol 1840 3.53E-05 5.20E+07 
Reboxetine 1820 2.92E-05 6.25E+07 
Camylofine 1830 3.42E-05 5.34E+07 
Papaverine  1820 3.13E-05 5.79E+07 
Yohimbine  1690 3.49E-05 4.84E+07 
Voriconazole 1840 3.22E-05 5.72E+07 
Alfacalcidol 1790 3.15E-05 5.67E+07 
Cilostazol 1740 3.35E-05 5.20E+07 
Azelastine 1680 3.76E-05 4.47E+07 
Etretinate 1750 3.52E-05 4.98E+07 
Fluoxetine  1660 3.20E-05 5.18E+07 
Norcyclobenzaprine 449 4.34E-05 1.04E+07 
Lovastatin 159 7.49E-05 2.13E+06 
Budesonide 2750 2.55E-05 1.08E+08 
Zaleplon 5440 6.72E-06 8.09E+08 
Diclofenac 1210 1.82E-05 6.62E+07 
Exemestane 2650 7.70E-07 3.44E+09 
Xylazine 5250 4.96E-05 1.06E+08 
Celiprolol 5340 3.18E-05 1.68E+08 
Zopiclone 6130 5.09E-05 1.21E+08 
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Lofexidine 4000 9.12E-05 4.39E+07 
Zafirlukast 733 9.52E-05 7.70E+06 
Rimantadine  91.9 1.08E-04 854000 
Ipsapirone 260 3.11E-05 8.37E+06 
Hydroxychloroquine 303 3.10E-05 9.79E+06 
Thiocolchicoside 1800 9.15E-06 1.97E+08 
Clorsulon 2670 9.46E-06 2.82E+08 
Diosmin 500 7.97E-05 6.27E+06 
Diflorasone 609 5.62E-05 1.08E+07 
Ciclopirox ethanolamine 1570 7.21E-05 2.17E+07 
Tetramisole  45.9 0.0624 736 
Chloroquine 7330 0.0364 201000 
Mizolastine 981 9.22E-06 1.06E+08 
Amisulpride 949 1.02E-05 9.30E+07 
Althiazide 943 1.46E-05 6.46E+07 
6-Furfurylaminopurine 980 2.75E-05 3.57E+07 
Flumethasone 741 2.21E-05 3.36E+07 
Loratadine 623 8.25E-05 7.55E+06 
Nisoldipine 1970 5.45E-05 3.61E+07 
Zonisamide 2440 6.15E-05 3.96E+07 
Irsogladine 562 1.02E-04 5.49E+06 
Sulfamethizole 395 7.18E-05 5.50E+06 
Medrysone 2780 1.22E-04 2.27E+07 
Monensin 3100 3.72E-05 8.35E+07 
Dydrogesterone 4370 3.63E-05 1.20E+08 
Opipramol di 9940 1.48E-05 6.74E+08 
Pranoprofen 1080 2.11E-05 5.09E+07 
Estropipate 2320 8.73E-06 2.66E+08 
Irinotecan 3150 7.54E-05 4.18E+07 
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Furaltadone  2330 1.21E-06 1.92E+09 
Ethoxyquin 51.4 1.36E-04 378000 
Alclometasone 1910 3.86E-05 4.96E+07 
Norgestrel-(-)-D 2700 2.26E-05 1.20E+08 
Fluocinonide 3160 1.61E-05 1.97E+08 
Alexidine di 1470 2.38E-05 6.16E+07 
Proadifen  1010 9.53E-05 1.06E+07 
Trihexyphenidyl-D,L  322 1.24E-04 2.59E+06 
Succinylsulfathiazole 336 1.12E-04 3.00E+06 
Famprofazone 702 9.69E-05 7.25E+06 
Bromopride 131 1.32E-04 993000 
Chlorcyclizine  1400 1.59E-04 8.77E+06 
Diphenylpyraline  1600 1.03E-04 1.55E+07 
Sulfachloropyridazine 245 9.73E-05 2.52E+06 
Cefuroxime 1070 1.70E-05 6.26E+07 
Dienestrol 1130 7.14E-05 1.58E+07 
Digoxigenin 140 2.67E-05 5.25E+06 
Clioquinol 241 3.31E-05 7.28E+06 
Bucladesine 2680 2.04E-05 1.31E+08 
Suprofen 2050 1.04E-05 1.97E+08 
Deflazacort 1160 6.57E-05 1.77E+07 
Benzthiazide 310 4.10E-06 7.56E+07 
S-(+)-ibuprofen 30.4 4.18E-05 728000 
Cefoxitin 420 3.47E-05 1.21E+07 
    
Carbenoxolone 2350 5.45E-06 4.31E+08 
Iocetamic acid 2350 1.12E-05 2.10E+08 
Nitrendipine 303 8.54E-05 3.55E+06 
Trimeprazine 188 5.44E-05 3.45E+06 
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Rolipram 1580 2.30E-05 6.85E+07 
Idazoxan  1140 1.38E-05 8.23E+07 
Quinapril 3300 1.80E-05 1.83E+08 
Ketorolac tromethamine 315 9.53E-05 3.31E+06 
Nylidrin 1670 3.93E-05 4.25E+07 
Doxazosin 2090 1.13E-05 1.85E+08 
S(-)Eticlopride  3260 1.80E-05 1.81E+08 
    
Baclofen 302 6.49E-05 4.65E+06 
Pindolol 2480 1.41E-04 1.75E+07 
Hydroflumethiazide 3080 1.45E-04 2.13E+07 
Sulfathiazole 4.11 1.73E-04 23700 
Idoxuridine 3390 1.47E-05 2.30E+08 
Captopril 809 1.96E-05 4.12E+07 
Antipyrine, 4-hydroxy 676 4.82E-05 1.40E+07 
Famotidine 899 8.93E-05 1.01E+07 
Nomifensine 927 1.72E-04 5.40E+06 
Chloramphenicol 3310 1.23E-04 2.68E+07 
Naloxone  3620 2.48E-05 1.46E+08 
Lidocaine  2260 1.31E-04 1.73E+07 
Pirenzepine 132 1.02E-04 1.29E+06 
Minaprine 2930 0.00178 1.65E+06 
Acebutolol  5130 0.00183 2.81E+06 
Dipyridamole 1780 0.00151 1.18E+06 
Dihydrostreptomycin 390 4.18E-05 9.33E+06 
Pentylenetetrazole 2280 2.30E-05 9.89E+07 
Chlorzoxazone 2600 3.47E-05 7.49E+07 
Ornidazole 2290 2.45E-05 9.32E+07 
Hydralazine  2390 2.85E-05 8.41E+07 
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Mexiletine  5200 9.21E-05 5.64E+07 
Glutethimide, para-amino 2750 1.47E-05 1.87E+08 
Prilocaine  434 2.92E-06 1.49E+08 
Camptothecine (S,+) 89.6 7.87E-06 1.14E+07 
Mefexamide  1700 5.32E-05 3.19E+07 
Tiapride  4890 7.97E-05 6.13E+07 
Pramipexole 2360 2.73E-06 8.64E+08 
Deptropine 1110 7.57E-05 1.46E+07 
Moxonidine 1910 6.49E-05 2.94E+07 
Ranolazine 1060 1.41E-05 7.52E+07 
Cyclopentolate  1390 7.38E-05 1.88E+07 
Meropenem 1650 2.03E-05 8.14E+07 
Ramipril 2750 2.24E-05 1.23E+08 
Mephenytoin 2740 2.21E-05 1.24E+08 
Molindone  2780 2.35E-05 1.19E+08 
Mecamylamine  96.3 1.94E-06 4.95E+07 
Mepivacaine  3190 9.82E-06 3.25E+08 
Hyoscyamine (L)  371 5.67E-05 6.54E+06 
Proglumide 188 7.25E-05 2.59E+06 
Mirtazapine 2310 2.63E-05 8.79E+07 
Tulobuterol 266 6.29E-05 4.22E+06 
Iopamidol 214 4.81E-05 4.46E+06 
Theobromine 3420 4.57E-05 7.47E+07 
Modafinil 2490 7.48E-05 3.34E+07 
Lamivudine 1340 5.42E-05 2.48E+07 
Ritodrine  236 2.54E-05 9.31E+06 
Carisoprodol 449 3.05E-05 1.47E+07 
Debrisoquin 579 2.68E-05 2.16E+07 
Melatonin 183000 0.061 3.01E+06 
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Oxantel 81300 0.0541 1.50E+06 
Itopride 154000 0.0874 1.77E+06 
Atropine 587 4.98E-05 1.18E+07 
Eserine hemisulfate 639 3.14E-05 2.04E+07 
Cetirizine 1790 3.16E-05 5.66E+07 
Cyclizine  1810 4.26E-05 4.24E+07 
Fomepizole 2880 4.67E-06 6.18E+08 
Phenacetin 329 3.00E-05 1.10E+07 
Parthenolide 20700 0.0411 504000 
Isopyrin  2040 1.01E-05 2.03E+08 
Sulfamethoxypyridazine 1560 1.49E-05 1.04E+08 
Deferoxamine 1330 5.89E-05 2.26E+07 
Spiramycin 813 1.07E-04 7.58E+06 
Tramadol  238 6.78E-05 3.51E+06 
Eucatropine  1670 9.66E-06 1.73E+08 
Nadolol 1250 8.19E-05 1.52E+07 
Moxalactam 6.68 1.02E-04 65500 
Tetrahydroxy-1,4-quinone 3100 1.69E-05 1.83E+08 
Allantoin 2040 1.06E-05 1.94E+08 
Sulfacetamide sodic hydrate 1530 1.59E-04 9.60E+06 
Antipyrine 88 5.07E-05 1.74E+06 
Trichlorfon 346 1.34E-04 2.58E+06 
Ethosuximide 2280 2.30E-05 9.92E+07 
Mafenide  2450 2.95E-05 8.31E+07 
Ampyrone 1290 2.71E-05 4.77E+07 
Methocarbamol 19.1 1.97E-05 971000 
Dimaprit di 1700 1.44E-05 1.18E+08 
Alcuronium 2420 1.66E-05 1.46E+08 
Zalcitabine 77.6 2.11E-06 3.67E+07 
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Acetylcysteine 181 7.59E-05 2.39E+06 
Caffeine 72.1 3.43E-05 2.10E+06 
5-fluorouracil 503 2.03E-05 2.48E+07 
(R)-(+)-Atenolol 724 2.68E-05 2.71E+07 
Gemcitabine 3210 1.78E-05 1.80E+08 
Phenylpropanolamine  635 8.22E-05 7.72E+06 
Carbimazole 996 2.91E-05 3.42E+07 
Carteolol  1900 7.55E-06 2.51E+08 
Alizapride 14700 0.0702 210000 
Terbutaline 76.2 6.94E-05 1.10E+06 
Serotonin  1.05E+06 0.252 4.17E+06 
Acarbose 455 2.72E-05 1.67E+07 
Iohexol 1750 3.35E-05 5.22E+07 
Trimethadione 302 8.96E-05 3.37E+06 
Benfotiamine 189 1.27E-04 1.49E+06 
Metoprolol-(+,-) 1520 2.31E-05 6.57E+07 
Penicillamine 3900 8.29E-05 4.71E+07 
Acefylline 1290 7.82E-05 1.64E+07 
Secnidazole 1260 7.15E-05 1.76E+07 
Pempidine 1140 7.52E-05 1.51E+07 
Clodronate 292 1.22E-04 2.39E+06 
Guaifenesin 3420 1.19E-05 2.88E+08 
Dipyrone 1870 7.36E-06 2.54E+08 
Aminophylline 1500 1.62E-04 9.21E+06 
Aminohippuric acid 4380 1.02E-04 4.29E+07 
N-Acetyl-L-leucine 2760 2.19E-07 1.26E+10 
Xamoterol 15100 4.29E-05 3.51E+08 
Thonzonium 2530 1.08E-05 2.34E+08 
Diprophylline 89.5 1.33E-04 672000 
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Isoniazid 2390 2.71E-05 8.84E+07 
Dropropizine (R,S) 2600 1.78E-05 1.46E+08 
Metaraminol 1050 2.09E-06 5.04E+08 
Ethamsylate 323 4.85E-05 6.64E+06 
Spaglumic acid 361 4.91E-05 7.35E+06 
(-)-Isoproterenol  3900 1.86E-05 2.10E+08 
Dirithromycin 5890 4.31E-05 1.37E+08 
Iopromide 1370 8.36E-05 1.64E+07 
Theophylline 273 6.03E-05 4.52E+06 
Racepinephrine 2180 7.24E-06 3.01E+08 
Ascorbic acid 1100 8.14E-05 1.36E+07 
Methyldopa (L,-) 1020 2.61E-05 3.91E+07 
Cyclosporin A 1080 2.75E-05 3.94E+07 
Bambuterol  1060 2.80E-05 3.79E+07 
Kanamycin A 181000 0.072 2.51E+06 
Amikacin 48200 0.0692 696000 
Galanthamine 1750 3.72E-05 4.70E+07 
Carbidopa 1040 6.15E-05 1.69E+07 
Acipimox 915 6.81E-05 1.34E+07 
Trimetazidine 32.9 0.0596 552 
Tetraethylenepentamine penta 2710 4.75E-05 5.72E+07 
Mevalonic-D, L acid lactone 1150 1.80E-05 6.38E+07 
Ribostamycin 120 5.43E-05 2.20E+06 
Thimerosal 1490 5.13E-05 2.91E+07 
Amiprilose  1730 5.59E-05 3.09E+07 
Thioperamide 3080 1.32E-05 2.34E+08 
Flucytosine 275 1.38E-04 1.99E+06 
 
